

CITATION REPORT

List of articles citing

The coagulation cascade: initiation, maintenance, and regulation

DOI: 10.1021/bi00107a001

Biochemistry, 1991, 30, 10363-70.

Source: <https://exaly.com/paper-pdf/21935545/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1617	18 Snake Venom Hemorrhagic and Non-Hemorrhagic Metalloproteinases: Their Structure and Function Relationships. 1994 , 231-252		1
1616	Proteolytic processing and regulation. 1991 , 45, 239-43		22
1615	Components and assembly of the factor X activating complex. 1992 , 18, 311-23		38
1614	Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. 1992 , 176, 1521-9		412
1613	Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. 1992 , 89, 11832-6		333
1612	Bioregulatory roles for fibrin(ogen) on blood coagulation. 1992 , 39, 152-5		
1611	Proteases. 1992 , 2, 713-720		27
1610	Development and evaluation of ELISAs for factor XIII _A and XIII _B subunits in plasma. 1992 , 67, 73-9		11
1609	Purification of factor XIa inhibitor from human platelets. 1992 , 66, 397-408		20
1608	Structural and functional properties of snake venom prothrombin activators. 1992 , 30, 1515-27		93
1607	The mammalian blood platelet: its role in haemostasis, inflammation and tissue repair. 1992 , 107, 243-70		46
1606	Leeches to Hirulogs and Other Thrombin-directed Antithrombotics. 1992 , 6, 1121-1129		16
1605	Biology of Factor IX. 1992 , 6, 991-997		8
1604	Characterization of a clotting protein, isolated from plasma of the freshwater crayfish <i>Pacifastacus leniusculus</i> . 1993 , 213, 591-7		91
1603	Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S. 1993 , 217, 857-65		19
1602	Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis. 1993 , 84, 662-9		31
1601	Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities. 1993 , 335, 9-12		38

1600	Prothrombin Activation by Snake Venom Proteases. 1993 , 12, 155-173		4
1599	Translocation of spin-labeled phospholipids through plasma membrane during thrombin- and ionophore A23187-induced platelet activation. <i>Biochemistry</i> , 1993 , 32, 2337-44	3.2	63
1598	Identification and structural analysis of the tetrasaccharide NeuAc alpha(2-->6)Gal beta(1-->4)GlcNAc beta(1-->3)Fuc alpha 1-->O-linked to serine 61 of human factor IX. <i>Biochemistry</i> , 1993 , 32, 6539-47	3.2	102
1597	Inherited predisposition to thrombosis. 1993 , 72, 477-80		138
1596	A player of many parts: the spotlight falls on thrombin's structure. 1993 , 69, 1-58		416
1595	Isolation of intact modules from noncatalytic parts of vitamin K-dependent coagulation factors IX and X and protein C. 1993 , 222, 416-35		7
1594	Human factor IX and factor IXa. 1993 , 222, 96-128		40
1593	Tissue factor is expressed on monocytes during simulated extracorporeal circulation. 1993 , 72, 1075-81		95
1592	Elevation of factor XIa-alpha 1-antitrypsin complex levels in NIDDM patients with diabetic nephropathy. 1993 , 42, 233-8		12
1591	LexA cleavage and other self-processing reactions. 1993 , 175, 4943-50		142
1590	Tissue factor contributes to microvascular defects after focal cerebral ischemia. 1993 , 24, 847-53; discussion 847		95
1589	Structural analysis of O-linked sugar chains in human blood clotting factor IX. 1993 , 114, 763-5		13
1588	Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. 1994 , 14, 483-8		16
1587	Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. 1994 , 14, 824-30		35
1586	Modulation of Protein Function by Lipids. 1994 , 40, 319-354		32
1585	Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. 1994 , 91, 1396-400		281
1584	Protein engineering of the hydrophobic domain of human factor IX. 1994 , 7, 1121-7		6
1583	Serpins are suicide substrates: implications for the regulation of proteolytic pathways. 1994 , 20, 410-6		19

1582	A review of studies of the activation of the blood coagulation mechanism in chimpanzees (<i>Pan troglodytes</i>). 1994 , 23, 280-4		2
1581	A simple activity assay for thrombin and hirudin. 1994 , 13, 367-73		24
1580	Evolution of prothrombin: isolation and characterization of the cDNAs encoding chicken and hagfish prothrombin. 1994 , 38, 177-87		22
1579	Lipid dynamics and peripheral interactions of proteins with membrane surfaces. 1994 , 73, 181-207		135
1578	Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169. <i>Biochemistry</i> , 1994 , 33, 5167-71	3.2	49
1577	Crayfish β macroglobulin as a substrate for transglutaminases. 1994 , 108, 65-72		12
1576	Loss of phospholipid asymmetry in human platelet plasma membrane after 1-12 days of storage. An ESR study. 1994 , 222, 1033-40		15
1575	Probing the structure of hirudin from <i>Hirudinaria manillensis</i> by limited proteolysis. Isolation, characterization and thrombin-inhibitory properties of N-terminal fragments. 1994 , 226, 323-33		31
1574	Role of hemocyte-derived granular components in invertebrate defense. 1994 , 712, 102-16		39
1573	Ca ²⁺ -dependent interactions between Gla and EGF domains in human coagulation factor IX. <i>Biochemistry</i> , 1994 , 33, 478-85	3.2	26
1572	Resistance to activated protein C as a basis for venous thrombosis. 1994 , 330, 517-22		998
1571	The binding of natural variants of human factor IX to endothelial cells. 1994 , 341, 74-8		3
1570	Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. 1994 , 74, 155-61		45
1569	Effect of gamma carboxylation on prothrombinase inhibitory activity of catalytically inactive factor XA. 1994 , 75, 427-36		6
1568	Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. 1994 , 344, 1192-3		85
1567	Coagulation factors and their inhibitors. 1994 , 4, 823-32		57
1566	Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. <i>Biochemistry</i> , 1994 , 33, 10864-70	3.2	136
1565	Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. 1994 , 297 (Pt 1), 131-6		38

1564	Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. 1994 , 302 (Pt 1), 305-12	56
1563	Vitamin K-dependent protein S in Leydig cells of human testis. 1994 , 302 (Pt 3), 845-50	29
1562	Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin. 1994 , 298 (Pt 2), 507-10	7
1561	First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. 1994 , 91, 3574-8	54
1560	An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. 1995 , 92, 5977-81	159
1559	Thrombosis and the pharmacology of antithrombotic agents. 1995 , 29, 892-905	39
1558	Linkage at steady state: allosteric transitions of thrombin. 1995 , 259, 127-44	11
1557	Recombinant soluble human tissue factor secreted by <i>Saccharomyces cerevisiae</i> and refolded from <i>Escherichia coli</i> inclusion bodies: glycosylation of mutants, activity and physical characterization. 1995 , 310 (Pt 2), 605-14	82
1556	Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. 1995 , 312 (Pt 2), 357-65	103
1555	Vitamin K nutrition and osteoporosis. 1995 , 125, 1812-21	126
1554	Thrombophilia: the discovery of activated protein C resistance. 1995 , 33, 135-75	6
1553	Liver-specific expression of the human factor VII gene. 1995 , 92, 12347-51	38
1552	Identification of two novel mutations in non-Jewish factor XI deficiency. 1995 , 90, 916-20	35
1551	Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. 1995 , 237, 221-7	57
1550	Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. 1995 , 75, 712-9	59
1549	Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex. 1995 , 22, 419-25	22
1548	Quantitative measurements of the cooperativity in an EF-hand protein with sequential calcium binding. 1995 , 4, 1038-44	38
1547	Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins. 1995 , 2, 504-9	130

1546	Nafamostat Mesilate. 1995 , 13, 51-65	37
1545	Cyclotheonamide derivatives: synthesis and thrombin inhibition. Exploration of specific structure-function issues. 1995 , 3, 1025-38	29
1544	Thrombin active site inhibitors. 1995 , 3, 999-1007	81
1543	Amide and alpha-keto carbonyl inhibitors of thrombin based on arginine and lysine: synthesis, stability and biological characterization. 1995 , 3, 1063-78	29
1542	Effect of phospholipid membranes on thrombin activity. 1995 , 38, 105-109	1
1541	Tissue thromboplastin. 1995 , 348, 305-307	
1540	Inflammatory cell participation in coagulation. 1995 , 6, 269-74	21
1539	Procoagulant, anticoagulant and fibrinolytic activities in llama plasma. 1995 , 5, 125-129	6
1538	Xa receptor EPR-1. 1995 , 9, 860-5	87
1537	Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. 1995 , 9, 946-55	323
1536	Differential Expression of Human Tissue Factor in Normal Mammary Epithelial Cells and in Carcinomas. 1995 , 1, 153-160	21
1535	Characterization of the 5'-flanking region of the gene for the alpha chain of human fibrinogen. 1995 , 270, 28342-9	34
1534	Hemostatic profile of bovine ovarian follicular fluid. 1995 , 73, 624-9	23
1533	Molecular genetics of venous thromboembolism. 1995 , 27, 187-92	16
1532	Development of a novel recombinant serpin with potential antithrombotic properties. 1995 , 270, 11866-71	37
1531	Localization of factor IXa and factor VIIIa interactive sites. 1995 , 270, 27087-92	43
1530	Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. 1995 , 270, 14884-90	44
1529	High affinity Ca(2+)-binding site in the serine protease domain of human factor VIIa and its role in tissue factor binding and development of catalytic activity. 1995 , 270, 15523-30	52

1528	Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. 1995 , 9, 2020-33		313
1527	Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. <i>Biochemistry</i> , 1995 , 34, 10383-92	3.2	93
1526	Episelection: novel Ki approximately nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface. <i>Biochemistry</i> , 1995 , 34, 8264-80	3.2	95
1525	NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: a symmetric tetramer. <i>Biochemistry</i> , 1995 , 34, 11399-409	3.2	55
1524	Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin. <i>Biochemistry</i> , 1995 , 34, 11537-44	3.2	23
1523	Proteinase inhibitors from the European medicinal leech <i>Hirudo medicinalis</i> : structural, functional and biomedical aspects. 1995 , 16, 215-313		28
1522	Isolation and properties of a blood coagulation factor X activator from the venom of king cobra (<i>Ophiophagus hannah</i>). 1995 , 33, 1263-76		39
1521	The protein C anticoagulant system: inherited defects as basis for venous thrombosis. 1995 , 77, 1-43		234
1520	Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. 1995 , 79, 1-47		77
1519	Developmental expression of protein C and protein S in the rat. 1995 , 78, 407-19		16
1518	Prothrombin Molise I: documentation of a second incidence of replacement of a critical Arg near the active site. 1995 , 80, 363-6		5
1517	The hemostatic profile of equine ovarian follicular fluid. 1995 , 77, 45-54		20
1516	Pharmacological characterization of a new 4-amidinophenyl-alanine thrombin-inhibitor (CRC 220). 1995 , 77, 357-68		18
1515	Calculation of relative binding free energies and configurational entropies: a structural and thermodynamic analysis of the nature of non-polar binding of thrombin inhibitors based on hirudin55-65. 1995 , 253, 473-92		42
1514	The S100 family protein MRP-14 (S100A9) has homology with the contact domain of high molecular weight kininogen. 1995 , 371, 271-5		19
1513	Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. 1995 , 9, 3-15		22
1512	Interactions of hirudin-based inhibitor with thrombin: critical role of the IleH59 side chain of the inhibitor. <i>Biochemistry</i> , 1995 , 34, 8708-14	3.2	12
1511	An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. 1995 , 90, 432-7		20

1510	Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site. 1996 , 71, 2830-9		45
1509	Engineering factor X fusions for expression in <i>Pichia pastoris</i> . 1996 , 799, 397-400		8
1508	Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group. 1996 , 39, 3039-43		65
1507	Integrin receptor GPIIb/IIIa bound state conformation of the fibrinogen gamma-chain C-terminal peptide 400-411: NMR and transfer NOE studies. <i>Biochemistry</i> , 1996 , 35, 4434-44	3.2	22
1506	Structure-based understanding of ligand affinity using human thrombin as a model system. <i>Biochemistry</i> , 1996 , 35, 9690-9	3.2	33
1505	X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. 1996 , 271, 29988-92		244
1504	Cell biology of tissue factor, the principal initiator of blood coagulation. 1996 , 81, 1-41		358
1503	Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX. 1996 , 81, 65-73		5
1502	Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. 1996 , 83, 117-26		41
1501	Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. 1996 , 83, 199-216		73
1500	Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex. 1996 , 84, 73-81		5
1499	Isolation and characterization of two cDNAs from Atlantic cod encoding two distinct psychrophilic elastases. 1996 , 113, 795-801		21
1498	Anticoagulants in vector arthropods. 1996 , 12, 430-7		39
1497	RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen gamma-chain C-terminal peptide. 1996 , 378, 79-82		8
1496	The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution. 1996 , 256, 144-59		98
1495	Endothelial cell injury in cardiovascular surgery: the procoagulant response. 1996 , 62, 1549-57		60
1494	Structural analysis of a biologically active echistatin analogue des(46-49)-[Ala8,37]-echistatin gamma with three disulfide bonds by 2D-NMR and computer graphics. 1996 , 220, 246-54		7
1493	Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. 1996 , 28, 1858-65		21

1492	Extracellular calcium-binding proteins. 1996 , 8, 609-17		80
1491	High-affinity calcium-binding site in the gamma-carboxyglutamic acid domain of bovine factor VII. <i>Biochemistry</i> , 1996 , 35, 13826-32	3.2	3
1490	Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. <i>Biochemistry</i> , 1996 , 35, 266-72	3.2	133
1489	Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications. 1996 , 5, 480-7		113
1488	Coagulation for Blood Bankers. 1996 , 16, 837-871		
1487	Residue 225 determines the Na(+)-induced allosteric regulation of catalytic activity in serine proteases. 1996 , 93, 10653-6		139
1486	Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. 1996 , 93, 14379-84		170
1485	Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. 1996 , 93, 6258-63		297
1484	Hereditary Thrombophilic Disease Associated with Defects in the Protein C Anticoagulant System. 1996 , 1, 227-37		
1483	Cellular consequences of thrombin-receptor activation. 1996 , 313 (Pt 2), 353-68		324
1482	Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. 1996 , 313 (Pt 2), 467-72		49
1481	Tissue Factor residue Asp44 regulates catalytic function of the bound proteinase Factor VIIa. 1996 , 315 (Pt 1), 145-51		15
1480	Interactions of integrin GPIIb/IIIa-derived peptides with fibrinogen investigated by NMR spectroscopy. 1996 , 315 (Pt 1), 161-70		5
1479	Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. 1996 , 319 (Pt 3), 873-9		75
1478	Cleavage of the thrombin receptor: identification of potential activators and inactivators. 1996 , 320 (Pt 1), 335-41		52
1477	The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. 1996 , 93, 10212-6		454
1476	Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. 1996 , 235, 310-6		64
1475	The anticoagulant effect of the human secretory phospholipase A2 on blood plasma and on a cell-free system is due to a phospholipid-independent mechanism of action involving the inhibition of factor Va. 1996 , 237, 778-85		32

1474	Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design. 1996 , 4, 1353-62	102
1473	Review of conformation-specific affinity purification methods for plasma vitamin K-dependent proteins. 1996 , 9, 211-218	19
1472	Blood coagulation profile of the Asian elephant (<i>Elephas maximus</i>). 1996 , 15, 413-423	9
1471	Tripeptidyl pyridinium methyl ketones as potent active site inhibitors of thrombin. 1996 , 6, 1677-1682	9
1470	Reversible modification of tissue-type plasminogen activator by methylphosphonate esters. 1996 , 4, 523-9	5
1469	(N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors. 1996 , 6, 2913-2918	14
1468	Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif. 1996 , 6, 2947-2952	17
1467	Scavenger receptors in innate immunity. 1996 , 8, 20-8	253
1466	Developments in antithrombotic therapy: state of the art anno 1996. 1996 , 18, 195-203	4
1465	Clearance of human factor XIa-inhibitor complexes in rats. 1996 , 93, 950-4	12
1464	Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. 1996 , 95, 738-46	21
1463	Structure of a bovine thrombin-hirudin ₅₁₋₆₅ complex determined by a combination of molecular replacement and graphics. Incorporation of known structural information in molecular replacement. 1996 , 52, 453-64	5
1462	Functionality map analysis of the active site cleft of human thrombin. 1996 , 10, 1-10	23
1461	In vivo immunosuppression by targeting a novel protease receptor. 1996 , 380, 352-6	30
1460	Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. 1996 , 384, 66-8	232
1459	Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. 1996 , 271, 1243-8	20
1458	Activated protein C resistance in young adults with central retinal vein occlusion. 1996 , 80, 200-2	65
1457	Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. 1996 , 271, 12913-8	74

1456	The influence of biomaterials on inflammatory responses to cardiopulmonary bypass. 1996 , 11, 220-8	8
1455	Identification of a factor IX binding site on the third apple domain of activated factor XI. 1996 , 271, 29023-8	80
1454	Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid. 1996 , 271, 20985-8	16
1453	Ca ²⁺ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. 1996 , 271, 25332-7	56
1452	Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity. 1996 , 271, 30685-91	23
1451	Role of Thrombin and Plasminogen Activators, Essential Proteases of the Coagulation and Fibrinolysis Cascades, in Fibrin Homeostasis and Vascular Cell Activation. 1996 , 45-60	
1450	Homology Modeling and Molecular Dynamics Simulations of the Gla Domains of Human Coagulation Factor IX and Its G[12]A Mutant. 1996 , 100, 2475-2479	8
1449	Control mechanisms in thrombin generation. 1996 , 22, 303-8	25
1448	The management of abnormalities of hemostasis in acute liver failure. 1996 , 16, 403-14	70
1447	Mutations within the reactive-site region of human pancreatic secretory trypsin inhibitor confer alpha-thrombin and factor Xa inhibitory activities. 1997 , 61, 389-91	2
1446	Scott syndrome: an inherited defect of the procoagulant activity of platelets. 1997 , 8, 117-24	32
1445	Selective loss of fibrinogen clotting in a loop-less thrombin. 1997 , 272, 19649-51	30
1444	Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN. 1997 , 272, 20721-9	43
1443	Characterization of placental bikunin, a novel human serine protease inhibitor. 1997 , 272, 12209-14	87
1442	Conformation of factor VIIa stabilized by a labile disulfide bond (Cys-310-Cys-329) in the protease domain is essential for interaction with tissue factor. 1997 , 272, 25724-30	23
1441	Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. 1997 , 272, 4367-77	147
1440	Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer study. 1997 , 272, 30160-6	44
1439	Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. 1997 , 272, 8340-5	25

1438	Interaction of calcium with native and decarboxylated human factor X. Effect of proteolysis in the autolysis loop on catalytic efficiency and factor Va binding. 1997 , 272, 22037-45		40
1437	Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. 1997 , 272, 21582-8		155
1436	Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. 1997 , 94, 9058-62		84
1435	Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. 1997 , 94, 11845-50		109
1434	Prothrombin kringle 1 domain interacts with factor Va during the assembly of prothrombinase complex. 1997 , 321 (Pt 3), 729-35		43
1433	Crystal structure of fibrinogen-Aalpha peptide 1-23 (F8Y) bound to bovine thrombin explains why the mutation of Phe-8 to tyrosine strongly inhibits normal cleavage at Arg-16. 1997 , 326 (Pt 3), 815-22		17
1432	The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro. 1997 , 94, 7176-81		145
1431	Pyridinone-thrombin inhibitors. 1997 , 7, 651-654		2
1430	Counting Integral Numbers of γ -Carboxyglutamic Acids Per Peptide Chain Using Capillary Electrophoresis. 1997 , 20, 2009-2021		3
1429	Factor IX activation by factor XIa proceeds without release of a free intermediate. <i>Biochemistry</i> , 1997 , 36, 4074-9	3.2	32
1428	Refinement of the NMR solution structure of the gamma-carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca ²⁺ positions determined by a genetic algorithm. <i>Biochemistry</i> , 1997 , 36, 2132-8	3.2	47
1427	Site-specific interaction of thrombin and inhibitors observed by fluorescence correlation spectroscopy. 1997 , 73, 2195-200		37
1426	Synergistic stimulation of fibrinogen gelation by casein kinase II and polycationic compounds. 1997 , 42, 487-95		4
1425	Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. 1997 , 275, 547-50		420
1424	The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. 1997 , 269, 395-407		67
1423	Structural and functional aspects of calcium binding in extracellular matrix proteins. 1997 , 15, 569-80; discussion 581		52
1422	A peptide sequence from the EGF-2 like domain of FVII inhibits TF-dependent FX activation. 1997 , 86, 57-67		14
1421	Thrombin interaction with fibrin polymerization sites. 1997 , 86, 301-16		18

1420 Sphingosine stimulates thrombin-induced gelation of the fibrinogen. **1997**, 87, 331-7

1419 Expression of trypsin in vascular endothelial cells. **1997**, 409, 442-8 67

1418 Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. **1997**, 412, 295-300 44

1417 Endothelial cell injury in cardiovascular surgery: atherosclerosis. **1997**, 63, 885-94 66

1416 The Procoagulant Response to Injury. **1997**, 64, S16-S23 7

1415 Atherosclerosis. **1997**, 64, S47-S56 2

1414 Localization of an effective fibrin beta-chain polymerization site: implications for the polymerization mechanism. *Biochemistry*, **1997**, 36, 9381-7 3.2 8

1413 Comparison of in vitro function of neutrophils from cattle deficient in plasma factor XI activity and from normal animals. **1997**, 58, 121-31 12

1412 Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. **1997**, 272, 7983-94 95

1411 A Soluble Tissue Factor Mutant Is a Selective Anticoagulant and Antithrombotic Agent. **1997**, 89, 3219-3227 58

1410 A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities. **1997**, 94, 1739-44 59

1409 Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. **1997**, 17, 3049-56 23

1408 A Comparison of Murine and Human Factor XI. **1997**, 90, 1055-1064 30

1407 Chromogenic Substrates Selective for Activated Protein C. **1997**, 89, 2220-2221 12

1406 Interleukin-10 Inhibits Activation of Coagulation and Fibrinolysis During Human Endotoxemia. **1997**, 89, 2701-2705 128

1405 A Novel Degradation Pathway of Tissue Factor Pathway Inhibitor: Incorporation Into Fibrin Clot and Degradation by Thrombin. **1997**, 90, 1883-1892 40

1404 Functional Interactions Between the Thrombin Receptor and the T-Cell Antigen Receptor in Human T-Cell Lines. **1997**, 90, 1893-1901 20

1403 An In Vitro Analysis of the Combination of Hemophilia A and Factor VLEIDEN. **1997**, 90, 3067-3072 80

1402	Rational engineering of activity and specificity in a serine protease. 1997 , 15, 146-9		100
1401	New insights into the regulation of the blood clotting cascade derived from the X-ray crystal structure of bovine meizothrombin des F1 in complex with PPACK. 1997 , 5, 1681-93		55
1400	The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. 1997 , 16, 2977-84		71
1399	Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. 1997 , 16, 6626-35		60
1398	Qualitative modeling of normal blood coagulation and its pathological states using stochastic activity networks. 1997 , 20, 265-81		11
1397	PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. 1997 , 11, 193-207		62
1396	Molecular mechanisms of thrombin function. 1997 , 53, 701-30		146
1395	The co-crystal structure of unliganded bovine alpha-thrombin and prethrombin-2: movement of the Tyr-Pro-Pro-Trp segment and active site residues upon ligand binding. 1997 , 6, 1438-48		35
1394	Modulation of human alpha-thrombin activity with phosphonate ester inhibitors. 1997 , 5, 1531-41		5
1393	Critical role of W60d in thrombin allostery. 1997 , 64, 103-9		19
1392	Coagulation on biomaterials in flowing blood: some theoretical considerations. 1997 , 18, 1511-22		72
1391	Activation of blood coagulation at heparin-coated surfaces. 1997 , 37, 108-13		26
1390	Human umbilical vein endothelial cells express high affinity receptors for factor Xa. 1997 , 172, 36-43		30
1389	Molecular genetics of implantation in the mouse. 1997 , 21, 6-20		102
1388	Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry. <i>Biochemistry</i> , 1998 , 37, 1053-9	3.2	44
1387	Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation. 1998 , 78, 1121-7		6
1386	Effective application of fibrin sealant using a spray device with a double-tube structure. 1998 , 18, 345-349		7
1385	Secretory phospholipases and membrane polishing. 1998 , 19, 13-20		13

1384	Factor Xa inhibitors by classical and combinatorial chemistry. 1998 , 3, 223-231	32
1383	Prevention of venous thromboembolism in general surgery. 1998 , 11, 605-19	10
1382	Lipid-protein interactions in blood coagulation. 1998 , 1376, 433-53	205
1381	Anticoagulant thrombins. 1998 , 8, 340-50	14
1380	Metallionen als Coinhibitoren von Serin-Proteasen: ein neuer Ansatz bei der Suche nach hochaffinen und spezifischen Liganden. 1998 , 110, 1930-1932	
1379	Mapping the active site of factor Xa by selective inhibitors: an NMR and MD study. 1998 , 30, 264-74	10
1378	Confocal fluorescence and Raman microscopy in industrial research. 1998 , 276, 577-588	15
1377	Tissue factor is associated with the nonbacterial thrombotic endocarditis induced by a hypobaric hypoxic environment in rats. 1998 , 433, 375-9	13
1376	Changes of tissue factor activity on inflammatory stimulus and aging in rat. 1998 , 21, 549-54	6
1375	Soluble fibrin in plasma as a sign of activated coagulation in patients with pregnancy complications. 1998 , 77, 165-169	
1374	Diarylsulfonamides as selective, non-peptidic thrombin inhibitors. 1998 , 8, 1613-8	17
1373	Identification and SAR for a selective, nonpeptidyl thrombin inhibitor. 1998 , 8, 1697-702	10
1372	Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex. 1998 , 7, 243-53	12
1371	Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. 1998 , 7, 815-36	349
1370	Hinge bending within the cytokine receptor superfamily revealed by the 2.4 Å crystal structure of the extracellular domain of rabbit tissue factor. 1998 , 7, 1106-15	18
1369	Gene expression of prothrombin in the human kidney and its potential relevance to kidney stone disease. 1998 , 81, 666-71; discussion 671-2	19
1368	Molecular abnormality observed in a patient with coagulation factor X (FX) deficiency: a novel three-base-pair (CTT) deletion within the polypyrimidine tract of the FX intron D. 1998 , 102, 926-8	7
1367	Spatiotemporal dynamics of clotting and pattern formation in human blood. 1998 , 1425, 453-68	40

1366	Effects of Pallas' viper (<i>Agkistrodon halys pallas</i>) venom on blood coagulation and characterization of a prothrombin activator. 1998 , 36, 143-52		14
1365	Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. 1998 , 91, 297-304		56
1364	A peptide sequence from mouse tissue factor inhibits human tissue factor dependent factor X activation. 1998 , 92, 135-40		
1363	Calcium binding to the first EGF-like module of human factor IX in a recombinant fragment containing residues 1-85. Mutations V46E and Q50E each manifest a negligible increase in calcium affinity. 1998 , 421, 100-4		10
1362	Tetrahydro-isoquinoline-based factor Xa inhibitors. 1998 , 41, 4983-94		32
1361	Solution structure of the N-terminal EGF-like domain from human factor VII. <i>Biochemistry</i> , 1998 , 37, 10605-15	23	
1360	Nitrophorin-2: a novel mixed-type reversible specific inhibitor of the intrinsic factor-X activating complex. <i>Biochemistry</i> , 1998 , 37, 10681-90	3.2	49
1359	Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids. <i>Biochemistry</i> , 1998 , 37, 13507-15	3.2	28
1358	Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. <i>Biochemistry</i> , 1998 , 37, 3321-8	3.2	14
1357	Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. 1998 , 41, 437-50		45
1356	Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa. 1998 , 277, 959-71		48
1355	Site-Specific Thermodynamics: Understanding Cooperativity in Molecular Recognition. 1998 , 98, 1563-1592		76
1354	Expression of the second epidermal growth factor-like domain of human factor VII in <i>Escherichia coli</i> . 1998 , 66, 203-10		3
1353	Conformational stability of factor VIIa: biophysical studies of thermal and guanidine hydrochloride-induced denaturation. <i>Biochemistry</i> , 1998 , 37, 7203-12	3.2	17
1352	Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. 1998 , 13, 145-57		3
1351	Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies. <i>Biochemistry</i> , 1998 , 37, 6645-57	3.2	48
1350	Human protein S cleavage and inactivation by coagulation factor Xa. 1998 , 273, 11521-6		29
1349	Review. 1998 , 22, 472-483		1

- 1348 Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. **1998**, 273, 31203-8 50
- 1347 Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain. **1998**, 273, 222-7 31
- 1346 The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. **1998**, 273, 16140-5 51
- 1345 Allosteric effects of a monoclonal antibody against thrombin exosite II. *Biochemistry*, **1998**, 37, 15057-65_{3,2} 30
- 1344 Structural basis for cytokine hormone-receptor recognition and receptor activation. **1998**, 52, 67-108 45
- 1343 Pharmacological actions of sulodexide. **1998**, 24, 127-38 46
- 1342 Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. **1998**, 273, 4378-86 164
- 1341 Fibrin d-Dimer Levels in Preeclamptic Pregnancies with Birth of Small-for-Gestational-Age Neonates. **1998**, 17, 217-226 3
- 1340 New enzyme lineages by subdomain shuffling. **1998**, 95, 9813-8 49
- 1339 New antithrombotic agents. **1998**, 114, 715S-727S 24
- 1338 Soluble fibrin in plasma as a sign of activated coagulation in patients with pregnancy complications. **1998**, 77, 165-169 8
- 1337 Site-specific analysis of mutational effects in proteins. **1998**, 51, 59-119 40
- 1336 Prothrombin deficiency results in embryonic and neonatal lethality in mice. **1998**, 95, 7597-602 210
- 1335 Structural basis for chemical inhibition of human blood coagulation factor Xa. **1998**, 95, 6630-5 131
- 1334 Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. **1998**, 333 (Pt 1), 121-7 136
- 1333 Factor VIII and von Willebrand Factor. **1998**, 79, 456-465 107
- 1332 Proteolysis of Tissue Factor Pathway Inhibitor (TFPI) by Plasmin: Effect on TFPI Activity. **1998**, 80, 423-427 47
- 1331 Antithrombotic diamines. **1998**, 8, 329-332

1330	Blood Coagulation in Hemophilia A and Hemophilia C. 1998 , 91, 4581-4592	169
1329	The Molecular Basis for Cross-Reacting Material Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII. 1998 , 91, 538-548	40
1328	Activation of Clotting Factor XI Without Detectable Contact Activation in Experimental Human Endotoxemia. 1998 , 92, 3294-3301	40
1327	Identification of Mutations and Polymorphisms in the Factor XI Genes of an African American Family by Dideoxyfingerprinting. 1998 , 92, 3309-3317	35
1326	Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by Serpins. 1998 , 80, 82-86	19
1325	Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. 1998 , 273, 12089-94	66
1324	Lonomia obliqua Caterpillar Spicules Trigger Human Blood Coagulation via Activation of Factor X and Prothrombin. 1998 , 79, 539-542	48
1323	Hemostatic Factors and Inflammatory Disease. 1999 , 82, 858-864	42
1322	Transcriptional Expression of Tissue Factor Pathway Inhibitor, Thrombomodulin and von Willebrand Factor in Normal Human Tissues. 1999 , 82, 1047-1052	69
1321	Compound Heterozygosity for One Novel and One Recurrent Mutation in a Thai Patient with Severe Protein S Deficiency. 1999 , 81, 189-192	19
1320	Regulation of Prothrombinase Activity by Protein S. 1999 , 82, 80-87	34
1319	Activation of Plasma Procarboxypeptidase U in Different Mammalian Species Points to a Conserved Pathway of Inhibition of Fibrinolysis. 1999 , 82, 1718-1721	33
1318	Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. 1999 , 25, 273-89	51
1317	New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. 1999 , 25, 407-18	83
1316	The role of factor XI in coagulation: a matter of revision. 1999 , 25, 419-28	33
1315	Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass : relationship to increased thrombin generation and heparin concentration. 1999 , 19, 248-54	23
1314	Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. 1999 , 274, 14926-35	206
1313	Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition. 1999 , 274, 28225-32	17

1312	A conotoxin from <i>Conus textile</i> with unusual posttranslational modifications reduces presynaptic Ca ²⁺ influx. 1999 , 96, 5758-63	114
1311	Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction. 1999 , 274, 29087-93	19
1310	An integrated study of fibrinogen during blood coagulation. 1999 , 274, 22862-70	92
1309	Mechanisms of antithrombotic drugs. 1999 , 46, 297-324	9
1308	Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX. 1999 , 274, 36373-8	54
1307	Review: infectious diseases and coagulation disorders. 1999 , 180, 176-86	135
1306	Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors. 1999 , 96, 10968-75	45
1305	Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. 1999 , 274, 18477-86	60
1304	Factor Xa inhibitors. 1999 , 9, 931-953	28
1303	Identification and characterization of the sodium-binding site of activated protein C. 1999 , 274, 4970-6	37
1302	Structure of human factor VIIa and its implications for the triggering of blood coagulation. 1999 , 96, 8925-30	148
1301	Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. 1999 , 274, 25317-29	57
1300	Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. 1999 , 96, 3114-9	188
1299	Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. 1999 , 274, 24171-5	36
1298	Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. 1999 , 96, 11054-61	222
1297	The crayfish plasma clotting protein: a vitellogenin-related protein responsible for clot formation in crustacean blood. 1999 , 96, 1965-70	181
1296	Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications. 1999 , 9, 835-40	12
1295	Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA. 1999 , 9, 2539-44	24

1294	Separation of human vitamin K-dependent coagulation proteins using hydrophobic interaction chromatography. 1999 , 736, 77-88	10
1293	Human plasma kallikrein and tissue kallikrein binding to a substrate based on the reactive site of a factor Xa inhibitor isolated from Bauhinia unguolata seeds. 1999 , 45, 145-9	29
1292	Identification of a novel mutation in a non-Jewish factor XI deficient kindred. 1999 , 104, 44-9	25
1291	Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. 1999 , 265, 539-48	36
1290	Crystal structures of the membrane-binding C2 domain of human coagulation factor V. 1999 , 402, 434-9	230
1289	Production of highly purified clotting factor IX by a combination of different chromatographic methods. 1999 , 844, 119-28	31
1288	New Potential Therapeutic Modalities: aPC. 1999 , 3, 161-171	13
1287	The Role of the Contact System in the Pathogenesis of Septic Shock. 1999 , 3, 111-118	11
1286	New resorbable polymeric systems with antithrombogenic activity. 1999 , 10, 873-8	15
1285	Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor. 1999 , 8, 2213-7	19
1284	Atlantic Cod Trypsin Y-Member of a Novel Trypsin Group. 1999 , 1, 598-607	18
1283	The role of type II phospholipase in membrane polishing in the human placenta. 1999 , 20, 293-300	18
1282	Bleeding and clotting problems during the perioperative period. 1999 , 56, 367-372	
1281	Hepatobiliary: periampullary carcinoma. 1999 , 56, 372-376	
1280	Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. 1999 , 7, 989-96	113
1279	Hypothermia in trauma patients. 1999 , 188, 685-96	119
1278	The thrombin receptor mediates functional activity-dependent neuromuscular synapse reduction via protein kinase C activation in vitro. 1999 , 38, 369-381	31
1277	Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach. 1999 , 34, 173-83	41

1276	Commentary: Lipids and Liposomes can do More Than Carry Drugs: Phosphatidylserine as a Regulator of Blood Coagulation. 1999 , 9, ix-xv		6
1275	Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. 1999 , 42, 458-77		407
1274	Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template. <i>Biochemistry</i> , 1999 , 38, 7969-77	3.2	9
1273	Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain. <i>Biochemistry</i> , 1999 , 38, 1957-66	3.2	48
1272	The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex. <i>Biochemistry</i> , 1999 , 38, 8948-60	3.2	15
1271	Venins de serpent et h̄mostasie. 1999 , 10, 195-206		1
1270	Antithrombotics. 1999 ,		2
1269	Functional phage display of leech-derived tryptase inhibitor (LDTI): construction of a library and selection of thrombin inhibitors. 1999 , 458, 11-6		31
1268	Dynamic character of the complex of human blood coagulation factor VIIa with the extracellular domain of human tissue factor: a normal mode analysis. 1999 , 463, 19-23		8
1267	Insertion of the Asp-Ser/Phe sequence in the P' position of hirutinin provides molecules having both antithrombin and disintegrin activity. 1999 , 93, 171-81		4
1266	Angiogenesis induced by tissue factor in vitro and in vivo. 1999 , 96, 183-9		19
1265	Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin. 1999 , 42, 1376-83		46
1264	Oral Thrombin Inhibitors: Challenges and Progress. 1999 , 367-396		3
1263	Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization. 1999 , 42, 3572-87		37
1262	Effect of dienogest on bleeding time, coagulation, fibrinolysis, and platelet aggregation in female rats. 1999 , 104, 93-101		12
1261	Properties of spin and fluorescent labels at a receptor-ligand interface. 1999 , 77, 2237-50		43
1260	Endothelial cell function and thrombosis. 1999 , 12, 329-41		113
1259	Activation markers of coagulation. 1999 , 12, 387-406		15

1258	Engineered recombinant factor VII Q217 variants with altered inhibitor specificities. <i>Biochemistry</i> , 1999 , 38, 10940-8	3.2	18
1257	Potent bivalent thrombin inhibitors: replacement of the scissile peptide bond at P(1)-P(1)' with arginyl ketomethylene isosteres. 1999 , 42, 3109-15		19
1256	Retinal vascular occlusion and deficiencies in the protein C pathway. 1999 , 128, 69-74		68
1255	Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. 1999 , 42, 2752-9		49
1254	Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. 1999 , 42, 2760-73		76
1253	Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. 1999 , 285, 2089-104		94
1252	Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla). 1999 , 127, 213-23		73
1251	The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. 1999 , 274, 37511-6		75
1250	Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition. 2000 , 350, 701		2
1249	Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition. 2000 , 350, 701-707		13
1248	Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule. 2000 , 349 Pt 3, 805-12		13
1247	Prothrombin cleaving antibody light chains. 2000 , 77, 115-29		7
1246	Structural analysis of N-linked sugar chains of human blood clotting factor IX. 2000 , 128, 175-80		24
1245	Peptide modified gold-coated polyurethanes as thrombin scavenging surfaces. 2000 , 49, 66-78		30
1244	Quantum similarity QSAR: Study of inhibitors binding to thrombin, trypsin, and factor Xa, including a comparison with CoMFA and CoMSIA methods. 2000 , 80, 265-282		15
1243	Modes of evolution in the protease and kringle domains of the plasminogen-prothrombin family. 2000 , 14, 469-78		17
1242	Application of monoliths for downstream processing of clotting factor IX. 2000 , 903, 21-32		35
1241	Hypothetical pathophysiology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy. 2000 , 42, 197-203		90

1240	Spectroscopic probing of the influence of calcium and the gla domain on the interaction between the first EGF domain in factor VIIa and tissue factor. 2000 , 267, 6204-11	7
1239	Increased effectiveness of fibrin sealant with a higher fibrin concentration. 2000 , 20, 27-31	9
1238	The specificity of biomolecular particle adhesion. 2000 , 173, 237-249	5
1237	The specificity of biomolecular particle adhesion. 2000 , 165, 25-38	8
1236	Isoxazolines and isoxazoles as factor Xa inhibitors. 2000 , 10, 685-9	62
1235	Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors. 2000 , 10, 963-6	89
1234	Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa. 2000 , 10, 217-21	13
1233	Selective boron-containing thrombin inhibitors--X-ray analysis reveals surprising binding mode. 2000 , 8, 2291-303	15
1232	Peptide exosite inhibitors of factor VIIa as anticoagulants. 2000 , 404, 465-70	200
1231	Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. 2000 , 404, 518-25	265
1230	Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. 2000 , 25, 53-9	109
1229	Nitrophorins and related antihemostatic lipocalins from <i>Rhodnius prolixus</i> and other blood-sucking arthropods. 2000 , 1482, 110-8	123
1228	Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. 2000 , 9, 223-8	16
1227	Conversion of a polysaccharide to nitric oxide-releasing form. Dual-mechanism anticoagulant activity of diazeniumdiolated heparin. 2000 , 10, 751-3	19
1226	Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. 2000 , 19, 5650-60	53
1225	Purification and characterization of a trypsin-like enzyme with fibrinolytic activity present in the abdomen of horn fly, <i>Haematobia irritans irritans</i> (Diptera: Muscidae). 2000 , 19, 515-21	23
1224	Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. 2000 , 43, 4398-415	44
1223	Evolution of serpin specificity: cooperative interactions in the reactive-site loop sequence of antithrombin specifically restrict the inhibition of activated protein C. 2000 , 51, 507-15	22

1222	Recent developments in structure-based drug design. 2000 , 78, 269-81	188
1221	[Recommendations of the International Cardiology Forum (ICF) 1998 on revision of the current guidelines for the diagnosis and treatment of unstable angina pectoris and nontransmural myocardial infarct]. 2000 , 89, 706-21	2
1220	Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. 2000 , 95, 569-576	43
1219	Prothrombin San Antonio: a single amino acid substitution at a Factor Xa activation site (Arg320 to His) results in dysprothrombinemia. 2000 , 95, 711-714	25
1218	Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. 2000 , 95, 1330-1335	116
1217	Effects of GP IIb/IIIa receptor antagonists on the activated clotting time of heparinized blood. 2000 , 95, 2189-2190	3
1216	Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. 2000 , 96, 3459-3465	51
1215	Severe Factor VII Deficiency Caused by a Novel Mutation His348 to Gln in the Catalytic Domain. 2000 , 83, 239-243	14
1214	Fluorescence properties and functional roles of tryptophan residues 60d, 96, 148, 207, and 215 of thrombin. 2000 , 275, 29513-20	10
1213	Rational design of a potent anticoagulant thrombin. 2000 , 275, 39827-30	73
1212	The impact of the factor V Leiden mutation on pregnancy. 2000 , 6, 301-6	24
1211	Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis. 2000 , 101, 2651-7	51
1210	The Drosophila caspase DRONC cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM. 2000 , 275, 27084-93	95
1209	Activation of clotting factors XI and IX in patients with acute myocardial infarction. 2000 , 20, 2489-93	64
1208	Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity. 2000 , 275, 229-34	14
1207	Normal endothelial cell function. 2000 , 9, 183-8	81
1206	The insect salivary protein, prolixin-S, inhibits factor IXa generation and Xase complex formation in the blood coagulation pathway. 2000 , 275, 6636-41	36
1205	SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor. 2000 , 275, 37340-6	42

1204	Role of monocytes in experimental <i>Staphylococcus aureus</i> endocarditis. 2000 , 68, 4818-21	34
1203	Inhibition of prothrombin activation by bothrojaracin, a C-type lectin from <i>Bothrops jararaca</i> venom. 2000 , 382, 123-8	16
1202	Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum. 2000 , 139, 461-75	45
1201	Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. 2000 , 156, 1217-25	96
1200	Amounts of selected coagulation factors in pre- and post-mortem follicular fluid are similar and do not correlate with molecular mass. 2000 , 63, 177-85	7
1199	Snake venom proteins acting on hemostasis. 2000 , 82, 851-9	218
1198	Protein C inhibitor (PAI-3): structure and multi-function. 2000 , 14, 133-145	12
1197	In vitro characterization of a novel factor Xa inhibitor, RPR 130737. 2000 , 99, 71-82	16
1196	Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2. 2000 , 100, 61-72	24
1195	In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors. 2000 , 100, 195-209	6
1194	Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor. 2000 , 98, 83-93	22
1193	¹ H, ¹⁵ N and (¹³ C assignments and secondary structure of the EGF-like module pair 3-4 from vitamin K-dependent protein S. 2000 , 475, 135-8	3
1192	Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. 2000 , 484, 87-91	118
1191	High levels of coagulation factor XI as a risk factor for venous thrombosis. 2000 , 342, 696-701	503
1190	Vitamin K-dependent proteins. 2000 , 58, 355-89	45
1189	Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. <i>Biochemistry</i> , 2000 , 39, 7398-405	3-2 33
1188	New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography. 2000 , 43, 1705-13	28
1187	Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoyl-piperidin-3-yl)-propanoic acid at P1. 2000 , 43, 361-8	14

1186	GRID/CPCA: a new computational tool to design selective ligands. 2000 , 43, 3033-44		179
1185	Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. 2000 , 97, 7754-9		455
1184	1,2-Dibenzamidobenzene inhibitors of human factor Xa. 2000 , 43, 859-72		48
1183	Human ovarian follicular fluid has functional systems for the generation and modulation of thrombin. 2000 , 73, 848-54		20
1182	Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. <i>Biochemistry</i> , 2000 , 39, 12534-42	3.2	109
1181	Monoclonal antibody light chain with prothrombinase activity. <i>Biochemistry</i> , 2000 , 39, 6459-65	3.2	87
1180	A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. <i>Biochemistry</i> , 2001 , 40, 9522-31	3.2	55
1179	High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. 2001 , 158, 277-87		239
1178	Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. <i>Biochemistry</i> , 2001 , 40, 1679-87	3.2	60
1177	Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. <i>Biochemistry</i> , 2001 , 40, 15341-8	3.2	146
1176	Tissue factor is not involved in the mitogenic activity of factor VIIa. 2001 , 281, 1074-7		6
1175	Proteinase activity in the white shrimp (<i>Penaeus vannamei</i>) clotting protein. 2001 , 287, 332-6		12
1174	A transglutaminase involved in the coagulation system of the freshwater crayfish, <i>Pacifastacus leniusculus</i> . Tissue localisation and cDNA cloning. 2001 , 11, 623-37		68
1173	Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. 2001 , 71, 330-8		58
1172	Novel intravenous antithrombins. 2001 , 141, 1043-7		10
1171	Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. 2001 , 130, 809-18		28
1170	Pharmacologic preservation of the hemostatic system during cardiac surgery. 2001 , 72, S1814-20		99
1169	Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin. 2001 , 1528, 167-76		26

1168	The endothelium: vascular control of haemostasis. 2001 , 95, 198-201		75
1167	Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. 2001 , 1512, 191-205		115
1166	Pharmacological characterization of a novel factor Xa inhibitor, FXV673. 2001 , 103, 309-24		30
1165	Antiphospholipid antibodies and the coagulation cascade. 2001 , 27, 573-86		7
1164	Thrombin. 2001 ,		1
1163	Estimation of binding affinities for selective thrombin inhibitors via Monte Carlo simulations. 2001 , 44, 1043-50		42
1162	Soluble phosphatidylserine binds to a single identified site in the C2 domain of human factor Va. <i>Biochemistry</i> , 2001 , 40, 8246-55	3.2	27
1161	Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor. <i>Biochemistry</i> , 2001 , 40, 3251-6	3.2	54
1160	Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa. <i>Biochemistry</i> , 2001 , 40, 9513-21	3.2	46
1159	The Role of Factor XI in a Dilute Thromboplastin Assay of Extrinsic Coagulation Pathway. 2001 , 85, 1055-1059		21
1158	Gene targeting in hemostasis prothrombin. 2001 , 6, d222-238		
1157	Gene targeting in hemostasis. Prothrombin. 2001 , 6, D222-38		2
1156	Plasma Lipoproteins, Hemostasis and Thrombosis. 2001 , 86, 386-394		80
1155	Measurement of a newly developed thrombomodulin addition activated partial thromboplastin time assay in patients with deep venous thrombosis. 2001 , 31, 26-31		
1154	Prothrombin Scranton: Substitution of an Amino Acid Residue Involved in the Binding of Na ⁺ (LYS-556 to THR) Leads to Dysprothrombinemia. 2001 , 85, 651-654		36
1153	Location of the platelet binding site in zymogen coagulation factor IX. 2001 , 12, 237-43		5
1152	An efficient refolding method for the preparation of recombinant human prethrombin-2 and characterization of the recombinant-derived alpha-thrombin. 2001 , 130, 269-77		15
1151	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor. 2001 , 49, 1237-44		16

1150	Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. 2001 , 97, 1907-14	53
1149	Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from <i>Porphyromonas gingivalis</i> . 2001 , 353, 325-31	16
1148	Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from <i>Porphyromonas gingivalis</i> . 2001 , 353, 325-331	29
1147	Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. 2001 , 97, 3117-22	73
1146	Antiplatelet agents in tissue factor-induced blood coagulation. 2001 , 97, 2314-22	86
1145	Defective binding of factor XI-N248 to activated human platelets. 2001 , 98, 125-9	28
1144	Regulatory Cascade. 2001 ,	
1143	Dual Effects of Sulfated D-galactans from the Red Algae <i>Botryocladia occidentalis</i> Preventing Thrombosis and Inducing Platelet Aggregation. 2001 , 86, 1540-1546	33
1142	Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. 2001 , 113, 94-9	31
1141	Contribution of tryptophan residues to the CD spectrum of the extracellular domain of human tissue factor: application in folding studies and prediction of secondary structure. 2001 , 268, 1118-28	26
1140	Optimization of a screening lead for factor VIIa/TF. 2001 , 11, 2253-6	48
1139	Synthesis of ¹³ C ₃ , ¹⁵ N ₄ -labeled factor Xa inhibitor. 2001 , 44, 247-256	12
1138	From proteases to proteomics. 2001 , 10, 892-904	111
1137	Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. 2001 , 7, 324-30	271
1136	Neutrophil-platelet interactions and their relevance to bovine respiratory disease. 2001 , 161, 41-62	10
1135	Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. 2001 , 9, 29-37	76
1134	The factor VII zymogen structure reveals reregistration of beta strands during activation. 2001 , 9, 627-36	88
1133	Demonstration of the extrinsic coagulation pathway in teleostei: identification of zebrafish coagulation factor VII. 2001 , 98, 8768-73	61

1132	The omega-loop region of the human prothrombin gamma-carboxyglutamic acid domain penetrates anionic phospholipid membranes. 2001 , 276, 23895-902	48
1131	Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. 2001 , 98, 13583-8	113
1130	Carboxypeptidase U at the interface between coagulation and fibrinolysis. 2001 , 7, 93-101	10
1129	Update on tumor cell procoagulant factors. 2001 , 106, 25-32	88
1128	The design and synthesis of noncovalent factor Xa inhibitors. 2001 , 1, 137-49	34
1127	Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity. 2001 , 276, 29195-9	34
1126	Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property. 2001 , 276, 17229-35	27
1125	Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. 2001 , 276, 23105-8	38
1124	Noncovalent interactions of the Apple 4 domain that mediate coagulation factor XI homodimerization. 2001 , 276, 6429-38	14
1123	Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. 2001 , 98, 1370-5	80
1122	Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation. 2001 , 16, 27-35	12
1121	Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis. 2001 , 156, 45-52	17
1120	New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction. 2001 , 161, 674-82	5
1119	Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. 2001 , 276, 24122-8	44
1118	NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. 2002 , 105, 2030-6	96
1117	Localization of the heparin binding exosite of factor IXa. 2002 , 277, 50756-60	46
1116	Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. 2002 , 277, 4892-9	51
1115	Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide. 2002 , 277, 15971-8	22

1114	Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa. 2002, 277, 25393-9	26
1113	Residues 88-109 of factor IXa are important for assembly of the factor X activating complex. 2002, 277, 5725-33	19
1112	Assessment of factor V, VII and X activities, the key coagulant proteins of the tissue factor pathway in poultry plasma. 2002, 43, 313-21	23
1111	Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. 2002, 99, 15333-8	94
1110	Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. 2002, 277, 26689-98	63
1109	The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody. 2002, 277, 35616-24	13
1108	A model for the stoichiometric regulation of blood coagulation. 2002, 277, 18322-33	288
1107	Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition. 2002, 277, 19823-30	25
1106	Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) is required for hepatocyte-specific expression of factor XI. 2002, 277, 18510-6	25
1105	Trypsin mutants for structure-based drug design: expression, refolding and crystallisation. 2002, 383, 1309-14	13
1104	Structure, function, and activation of coagulation factor VII. 2002, 3, 287-99	33
1103	Mammalian Proteinase Genes. 2002, 283-296	
1102	Thrombin generation and presence of thrombin receptor in ovarian follicles. 2002, 66, 1350-8	20
1101	Prothrombin kringle-2 activates cultured rat brain microglia. 2002, 168, 5805-10	31
1100	Peptidoglycan from Staphylococcus aureus induces tissue factor expression and procoagulant activity in human monocytes. 2002, 70, 3033-9	26
1099	Soluble phosphatidylserine triggers assembly in solution of a prothrombin-activating complex in the absence of a membrane surface. 2002, 277, 29765-73	28
1098	The 99 and 170 loop-modified factor VIIa mutants show enhanced catalytic activity without tissue factor. 2002, 277, 49027-35	19
1097	Proline-rich cell surface antigens of horseshoe crab hemocytes are substrates for protein cross-linking with a clotting protein coagulin. 2002, 277, 40084-90	43

1096	The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex. 2002 , 277, 5734-41		26
1095	Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. 2002 , 303, 993-1000		52
1094	Five things oculoplastic surgeons should know about the preoperative assessment of hemostasis. 2002 , 18, 396-401		2
1093	Activation of factor IX by erythrocyte membranes causes intrinsic coagulation. 2002 , 13, 489-96		31
1092	Redox control of tissue factor expression in smooth muscle cells and other vascular cells. 2002 , 352, 220-31		11
1091	Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. 2002 , 102, 425-434		19
1090	Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. 2002 , 102, 425		12
1089	Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, <i>Ixodes scapularis</i> : identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. 2002 , 99, 3602-12		224
1088	Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. 2002 , 100, 501-8		65
1087	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. 2002 , 50, 1187-94		23
1086	Chapter 9. Anticoagulants: Inhibitors of the factor VIIa/tissue factor pathway. 2002 , 37, 85-94		13
1085	Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. <i>Biochemistry</i> , 2002 , 41, 13556-69	3.2	23
1084	Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. <i>Biochemistry</i> , 2002 , 41, 2535-42	3.2	21
1083	Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. <i>Biochemistry</i> , 2002 , 41, 78-85	3.2	27
1082	Role of basic residues of the autolysis loop in the catalytic function of factor Xa. <i>Biochemistry</i> , 2002 , 41, 6780-8	3.2	55
1081	Intracellular localization of endothelial cell annexins is differentially regulated by oxidative stress. 2002 , 274, 254-63		29
1080	Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. 2002 , 163, 39-47		30
1079	Bivalirudin: a review of its potential place in the management of acute coronary syndromes. 2002 , 62, 841-70		22

1078	Over-expression and purification of active serine proteases and their variants from Escherichia coli inclusion bodies. 2002 , Chapter 21, Unit 21.11	
1077	SPATIO-TEMPORAL DYNAMICS OF BLOOD COAGULATION AND PATTERN FORMATION: A THEORETICAL APPROACH. 2002 , 12, 1985-2002	25
1076	SPATIO-TEMPORAL DYNAMICS OF BLOOD COAGULATION AND PATTERN FORMATION: AN EXPERIMENTAL STUDY. 2002 , 12, 1969-1983	17
1075	New targets for antithrombotic drugs. 2002 , 2, 227-35	6
1074	In vitro effect of a thrombin inhibition peptide selected by phage display technology. 2002 , 107, 365-71	11
1073	The influence of residue 190 in the S1 site of trypsin-like serine proteases on substrate selectivity is universally conserved. 2002 , 530, 220-4	25
1072	Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. 2002 , 322, 591-603	71
1071	Structure and dynamics of zymogen human blood coagulation factor X. 2002 , 82, 1190-206	63
1070	Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor. 2002 , 32, 991-7	69
1069	A Cyclic Pentapeptide Derived from the Second EGF-Like Domain of Factor VII Is an Inhibitor of Tissue Factor Dependent Coagulation and Thrombus Formation. 2002 , 87, 13-21	14
1068	Thrombin stimulates dissociation and induction of HSP27 via p38 MAPK in vascular smooth muscle cells. 2002 , 283, H941-8	21
1067	Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates. 2002 , 277, 20527-34	52
1066	Substitution of Gly-548 to Ala in the Substrate Binding Pocket of Prothrombin PerijlLeads to the Loss of Thrombin Proteolytic Activity. 2002 , 87, 282-287	11
1065	Enhancing the Anticoagulant Potency of Soluble Tissue Factor Mutants by Increasing their Affinity to Factor VIIa. 2002 , 87, 450-458	15
1064	New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. 2002 , 3, 313-39	59
1063	Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. 2002 , 22, 1036-41	19
1062	Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. 2002 , 1590, 123-30	28
1061	Evolution of enzyme cascades from embryonic development to blood coagulation. 2002 , 27, 67-74	253

1060	Studies of the receptor-bound conformation of alphaIIb beta3 antagonists by 15N-edited NMR spectroscopy. 2002 , 66, 326-38	2
1059	Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency. 2002 , 12, 1667-70	18
1058	Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. 2002 , 12, 1671-4	48
1057	Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors. 2002 , 12, 1657-61	11
1056	Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides. 2002 , 12, 1651-5	19
1055	Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines. 2002 , 10, 657-66	13
1054	Factor Va increases the affinity of factor Xa for prothrombin: a binding study using a novel photoactivable thiol-specific fluorescent probe. 2002 , 9, 485-94	13
1053	Thrombin-induced activation of cultured rodent microglia. 2000 , 75, 1539-47	143
1052	Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?. 2002 , 119, 310-22	10
1051	Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. 2002 , 99, 2448-54	104
1050	Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. 2002 , 45, 2749-69	72
1049	The contribution of factor Xa to exosite-dependent substrate recognition by prothrombinase. 2002 , 277, 9366-74	33
1048	Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest. 2003 , 21, 527-51. viii	18
1047	Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery. 2003 , 23, 772-87	4
1046	Thromboresistance of alkali- and heat-treated titanium metal formed with apatite. 2003 , 65, 409-16	17
1045	Design and evaluation of novel blood incubation systems for in vitro hemocompatibility assessment of planar solid surfaces. 2003 , 66, 379-90	55
1044	Endothelial cell functions. 2003 , 196, 430-43	479
1043	Proteinase-activated receptor activation by coagulation proteinases. 2003 , 59, 400-407	5

1042	Compound heterozygosity for two novel mutations in a severe factor XI deficiency. 2003 , 73, 279-84	20
1041	Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C. 2003 , 790, 183-97	30
1040	Identification and characterization of novel salivary thrombin inhibitors from the ixodidae tick, <i>Haemaphysalis longicornis</i> . 2003 , 270, 1926-34	75
1039	Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia. 2003 , 84, 1201-14	58
1038	The assembly of the factor X-activating complex on activated human platelets. 2003 , 1, 48-59	49
1037	Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. 2003 , 1, 263-8	96
1036	Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. 2003 , 1, 889-95	73
1035	Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma. 2003 , 1, 1785-90	43
1034	Factor XI apple domains and protein dimerization. 2003 , 1, 2340-7	23
1033	Oscar Ratnoff: his contributions to the golden era of coagulation research. 2003 , 122, 180-92	15
1032	Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant. 2003 , 35, 34-41	16
1031	An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa): a protein-protein docking and molecular dynamics refinement study. 2003 , 1, 2577-88	22
1030	Superantigens from <i>Staphylococcus aureus</i> induce procoagulant activity and monocyte tissue factor expression in whole blood and mononuclear cells via IL-1 beta. 2003 , 1, 2569-76	19
1029	Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors. 2003 , 13, 561-6	17
1028	Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors. 2003 , 13, 723-8	12
1027	Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library. 2003 , 13, 1795-9	27
1026	Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. 2003 , 17, 37-61, vi	34
1025	Conformation of a bound inhibitor of blood coagulant factor Xa. <i>Biochemistry</i> , 2003 , 42, 7942-9	3.2 11

1024	Type II transmembrane serine proteases. 2003 , 54, 167-206	43
1023	Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin. 2003 , 46, 1293-305	20
1022	Analyses of activity for factor Xa inhibitors based on Monte Carlo simulations. 2003 , 46, 5691-9	23
1021	The extended interactions and Gla domain of blood coagulation factor Xa. <i>Biochemistry</i> , 2003 , 42, 7959-66	23
1020	Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor. <i>Biochemistry</i> , 2003 , 42, 10619-26	3-2 7
1019	Screening of inhibitors using enzymes entrapped in sol-gel-derived materials. 2003 , 75, 2382-91	78
1018	Proteolysis in Carcinogenesis. 2003 , 137-149	4
1017	Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5. 2003 , 111, 293-9	5
1016	Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity. 2003 , 325, 963-77	30
1015	Cloning and expression of rat coagulation factor VII. 2003 , 109, 225-31	7
1014	Inflammatory response to cardiopulmonary bypass. 2003 , 75, S715-20	431
1013	A new blood coagulation inhibitor from the snake <i>Bothrops jararaca</i> plasma: isolation and characterization. 2003 , 308, 706-12	16
1012	Determination of the P1', P2' and P3' subsite-specificity of factor Xa. 2003 , 35, 221-5	15
1011	Exploring the active site of human factor Xa protein by NMR screening of small molecule probes. 2003 , 1, 4235-41	16
1010	A brief historical review of the waterfall/cascade of blood coagulation. 2003 , 278, 50819-32	100
1009	New antithrombotic drugs on the horizon. 2003 , 12, 781-97	31
1008	Substrate turnover and inhibitor binding as selection parameters in directed evolution of blood coagulation factor Xa. 2003 , 1, 1657-63	2
1007	Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa. 2003 , 278, 25032-8	29

1006	Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors. 2003 , 384, 1515-25	6
1005	Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles. 2003 , 278, 14614-21	18
1004	Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop. 2003 , 278, 4121-6	32
1003	The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. 2003 , 278, 7981-7	39
1002	Integral role of RhoA activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. 2003 , 23, 681-7	41
1001	Type II transmembrane serine proteases. 2003 , 90, 185-93	87
1000	Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex. 2003 , 278, 33312-8	38
999	Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. 2003 , 278, 52363-70	89
998	Mutations in autolytic loop-2 and at Asp554 of human prothrombin that enhance protein C activation by meizothrombin. 2003 , 278, 15015-22	5
997	Transcriptional regulation of limulus factor C: repression of an NFkappaB motif modulates its responsiveness to bacterial lipopolysaccharide. 2003 , 278, 49428-37	10
996	Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein. 2003 , 278, 9394-401	21
995	Thrombomodulin allosterically modulates the activity of the anticoagulant thrombin. 2003 , 100, 12051-6	47
994	Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. 2003 , 9, 2349-65	35
993	Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency. 2003 , 55, 114-5	23
992	G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. 2003 , 3, 1115-23	15
991	The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury. 2003 , 3, 193-8	14
990	Expression of proteinase-activated receptors in mouse microglial cells. 2003 , 14, 2373-7	34
989	New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. 2003 , 124, 364S-370S	37

988	Thrombin and fibrinolysis. 2003 , 124, 33S-9S	116
987	A novel serine protease predominately expressed in macrophages. 2003 , 374, 97-107	28
986	Characteristics of the hemostatic action of KFA-1411, an inhibitor of coagulation factor Xa (FXa), in humans and various animals. 2003 , 28, 25-34	4
985	Thrombin generation measurement in factor VII-depleted plasmas compared to inherited factor VII-deficient plasmas. 2003 , 33, 36-42	11
984	The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma. 2004 , 91, 912-8	13
983	The preparation of fluorescence-quenched probes for use in the characterization of human factor Xa substrate binding domains. 2004 , 9, 427-39	6
982	Mechanisms of Thrombosis and thrombolysis. 2004 , 785-798	
981	Object-oriented design for the specification of the blood clotting cascade. 2004 ,	0
980	Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. 2004 , 279, 53691-8	22
979	Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin. 2004 , 279, 54927-36	50
978	Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. 2004 , 279, 46981-94	37
977	Fish protein stimulated the fibrinolysis in rats. 2004 , 48, 348-56	14
976	Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex. 2004 , 279, 49019-25	22
975	Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. 2004 , 92, 444-50	79
974	Expression of developmental endothelial locus-1 in a subset of macrophages for engulfment of apoptotic cells. 2004 , 172, 3876-82	118
973	Low Protein C, Tissue Factor Pathway Inhibitor, and Antithrombin allow Sufficient Thrombin Generation in Neonatal Plasma. 2004 , 297-301	
972	Coumarin and isocoumarin as serine protease inhibitors. 2004 , 10, 3781-96	73
971	The critical role of the 185-189-loop in the factor Xa interaction with Na ⁺ and factor Va in the prothrombinase complex. 2004 , 279, 48262-9	39

970	Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. 2004 , 279, 17241-9	57
969	Active site-independent recognition of substrates and product by bovine prothrombinase: a fluorescence resonance energy transfer study. 2004 , 279, 20786-93	16
968	Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. 2004 , 101, 3939-44	74
967	Proteolytic shedding of the extracellular domain of photoreceptor cadherin. Implications for outer segment assembly. 2004 , 279, 42202-10	38
966	Role of the N-terminal epidermal growth factor-like domain of factor X/Xa. 2004 , 279, 24189-96	9
965	Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. 2004 , 21, 907-22	22
964	Novel missense mutation in the coagulation factor IX catalytic domain associated with severe haemophilia B--Factor IXDelhi. 2004 , 10, 550-2	2
963	Do platelets synthesize factor XI?. 2004 , 2, 1709-12	14
962	In vivo thrombin generation in neonates. 2004 , 2, 2071-2	12
961	Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. 2004 , 2, 452-8	20
960	Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?. 2004 , 204, 33-48	242
959	Comparative aspects of blood coagulation. 2004 , 168, 238-51	61
958	Acute coronary syndromes: initial evaluation and risk stratification. 2004 , 46, 379-92	18
957	Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions. 2004 , 17, 11-20	1
956	Incorporation of the fluorescent amino acid 7-azatryptophan into the core domain 1-47 of hirudin as a probe of hirudin folding and thrombin recognition. 2004 , 13, 1489-502	41
955	Proteins Entrapped in Silica Monoliths Prepared from Glyceroxysilanes. 2004 , 31, 343-348	43
954	Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review. 2004 , 19, 122-8	
953	Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation. 2004 , 18, 5-10	2

952	[From fibrinogen and hirudin to synthetic anticoagulants. Rational design of thrombin inhibitors]. 2004 , 33, 196-205			5
951	Prothrombin Shanghai: hypoprothrombinaemia caused by substitution of Glu29 by Gly. 2004 , 10, 94-7			7
950	Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis. 2004 , 24, 687-747			11
949	Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII. 2004 , 11, 1413-22			24
948	PNA-encoded protease substrate microarrays. 2004 , 11, 1351-60			126
947	Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics. 2004 , 39, 257-65			4
946	The protein structures that shape caspase activity, specificity, activation and inhibition. 2004 , 384, 201-32			665
945	Prevention of beta strand movement into a zymogen-like position does not confer higher activity to coagulation factor VIIa. <i>Biochemistry</i> , 2004 , 43, 14096-103	3.2		9
944	Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity. <i>Biochemistry</i> , 2004 , 43, 1223-9	3.2		15
943	RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. 2004 ,			
942	Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. 2004 , 47, 805-20			50
941	Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. 2004 , 47, 769-87			41
940	Zymogenic and enzymatic properties of the 70-80 loop mutants of factor X/Xa. 2004 , 13, 431-42			24
939	Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. 2004 , 64, 577-95			28
938	Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin. 2004 , 135, 577-82			21
937	Boophilus microplus tick larvae, a rich source of Kunitz type serine proteinase inhibitors. 2004 , 86, 643-9			43
936	RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. 2004 , 568, 10-4			24
935	Identification and characterization of a novel factor XIIa inhibitor in the hematophagous insect, <i>Triatoma infestans</i> (Hemiptera: Reduviidae). 2004 , 577, 512-6			57

934	Purification, identification, and characterization of elastase on erythrocyte membrane as factor IX-activating enzyme. 2004 , 316, 65-70	27
933	Biochemical characterization of prostasin, a channel activating protease. 2004 , 324, 953-63	69
932	Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor. 2004 , 324, 1227-33	10
931	Reduction in arthritis severity and modulation of immune function in tissue factor cytoplasmic domain mutant mice. 2004 , 164, 109-17	31
930	Active-site inactivated FVIIa decreases thrombosis and necrosis in a random skin flap model of acute ischemia. 2004 , 122, 263-73	9
929	Evaluation of phage display system and leech-derived tryptase inhibitor as a tool for understanding the serine proteinase specificities. 2004 , 425, 87-94	17
928	Heparin is much more than just an anticoagulant. 2004 , 18, 93-100	17
927	Variants of recombinant factor VIIa with increased intrinsic activity. 2004 , 41, 89-92	12
926	Peroxynitrite decreases rabbit tissue factor activity in vitro. 2004 , 98, 668-71, table of contents	6
925	Bivalirudin for endovascular intervention in acute ischemic stroke: case report. 2004 , 54, 218-22; discussion 222-3	22
924	Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. 2004 , 104, 128-34	76
923	Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. 2004 , 379, 497-503	41
922	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one skeleton. 2004 , 52, 406-12	12
921	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition. 2004 , 52, 459-62	9
920	Effect of the new Direct Thrombin Inhibitor Melagatran in Cord and Adult Plasma: an in-vitro Examination. 2005 , 277-287	
919	Rheological analyses of coagulation of blood from different individuals with special reference to procoagulant activity of erythrocytes. 2005 , 16, 355-63	15
918	Reviewing the reality: why we need to change. 2005 , 7, E15-E20	32
917	A classification system for cross-reactive material-negative factor XI deficiency. 2005 , 105, 4671-3	31

916	The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. 2005 , 106, 3055-7	17
915	Ixolaris: a factor Xa heparin-binding exosite inhibitor. 2005 , 387, 871-7	59
914	Polyethylene oxide surfaces of variable chain density by chemisorption of PEO-thiol on gold: adsorption of proteins from plasma studied by radiolabelling and immunoblotting. 2005 , 26, 5927-33	129
913	Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin. 2005 , 26, 6506-17	95
912	Argatroban-coupled Affi-Gel matrix for the purification of thrombin from plasma. 2005 , 42, 189-92	
911	In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. 2005 , 48, 1984-2008	50
910	Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations. 2005 , 95, 1177-87	23
909	Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. 2005 , 3, 695-702	199
908	Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 --> Thr (Prothrombin Vellore 1) mutation. 2005 , 3, 1446-53	17
907	Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. 2005 , 3, 2798-805	71
906	Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults. 2005 , 146, 1082-6	10
905	Structural biology and drug discovery. 2005 , 10, 895-907	261
904	Adenylyl cyclase-cAMP system inhibits thrombin-induced HSP27 in vascular smooth muscle cells. 2005 , 94, 573-84	5
903	Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. 2005 , 44, 4400-4	94
902	Quantifizierung von Kation- π -Wechselwirkungen in Protein-Ligand-Komplexen: Kristallstrukturanalyse eines Komplexes von Faktor Xa und einem quartären Ammonium-Ion-Liganden. 2005 , 117, 4474-4479	17
901	Purification and initial characterization of a novel protein with factor Xa activity from <i>Lonomia obliqua</i> caterpillar spicules. 2005 , 40, 405-12	11
900	Progress in the design of low molecular weight thrombin inhibitors. 2005 , 25, 66-92	47
899	An insertion mutation of the bovine Fii gene is responsible for factor XI deficiency in Japanese black cattle. 2005 , 16, 383-9	34

898	Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors. 2005 , 15, 5453-8	16
897	Improving small-diameter vascular grafts: from the application of an endothelial cell lining to the construction of a tissue-engineered blood vessel. 2005 , 19, 448-56	67
896	Regulation of high molecular weight bovine brain neutral protease by phospholipids in vitro. 2005 , 272, 145-9	1
895	Structure of human factor VIIa/tissue factor in complex with a peptide-mimetic inhibitor: high selectivity against thrombin by introducing two charged groups in P2 and P4. 2005 , 61, 169-73	5
894	Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. 2005 , 62, 1-13	80
893	Higher Concentrations of Heparin and Hirudin are Required to Inhibit Thrombin Generation in Tissue Factor-Activated Cord Compared to Adult Plasma. 2005 , 288-297	
892	Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology. 2005 , 6, 383-400	
891	Peptide Mimetic Factor VIIa Inhibitor: Importance of Hydrophilic Pocket in S2 Site to Improve Selectivity Against Thrombin. 2005 , 2, 177-181	3
890	Comparative analysis of prothrombin activators from the venom of Australian elapids. 2005 , 22, 1853-64	52
889	The affinity of protein C for the thrombin.thrombomodulin complex is determined in a primary way by active site-dependent interactions. 2005 , 280, 15471-8	16
888	Preparation and characterization of monoclonal antibodies to thrombomodulin. 2005 , 24, 189-96	1
887	Learning Surgery. 2005 ,	1
886	Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition. 2005 , 280, 32722-8	30
885	Thrombomodulin-independent activation of protein C and specificity of hemostatically active snake venom serine proteinases: crystal structures of native and inhibited Agkistrodon contortrix contortrix protein C activator. 2005 , 280, 39309-15	37
884	Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX. 2005 , 280, 23523-30	23
883	Hemextin AB complex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals cobra) venom that inhibits clot initiation and factor VIIa activity. 2005 , 280, 42601-11	55
882	Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma. 2005 , 57, 685-9	14
881	The systemic inflammatory response syndrome and cardiopulmonary bypass. 2005 , 3, 129-40	144

880	Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. 2005 , 304, 16-27		81
879	Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. 2005 , 48, 3290-312		61
878	34th Hemophilia Symposium. 2005 ,		
877	Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. 2005 , 48, 4511-25		90
876	Full and partial deuterium solvent isotope effect studies of alpha-thrombin-catalyzed reactions of natural substrates. 2005 , 127, 3760-6		9
875	Completed three-dimensional model of human coagulation factor va. Molecular dynamics simulations and structural analyses. <i>Biochemistry</i> , 2005 , 44, 13082-90	3.2	30
874	Functional mapping of charged residues of the 82-116 sequence in factor Xa: evidence that lysine 96 is a factor Va independent recognition site for prothrombin in the prothrombinase complex. <i>Biochemistry</i> , 2005 , 44, 10063-70	3.2	6
873	Akt regulates thrombin-induced HSP27 phosphorylation in aortic smooth muscle cells: function at a point downstream from p38 MAP kinase. 2005 , 77, 96-107		12
872	Novel interactions of large P3 moiety and small P4 moiety in the binding of the peptide mimetic factor VIIa inhibitor. 2005 , 326, 859-65		6
871	Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. 2005 , 327, 589-96		8
870	Transition state analysis of the complex between coagulation factor VIIa and tissue factor: suggesting a sequential domain-binding pathway. 2005 , 327, 789-93		3
869	Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. 2005 , 115, 135-42		10
868	The intriguing world of prothrombin activators from snake venom. 2005 , 45, 1133-45		102
867	Insights into enzyme structure and dynamics elucidated by amide H/D exchange mass spectrometry. 2005 , 433, 34-46		160
866	Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity. 2005 , 14, 1171-80		10
865	3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. 2005 , 48, 7592-603		55
864	Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. 2006 , 20, 151-60		104
863	Thrombin-cofactor interactions: structural insights into regulatory mechanisms. 2006 , 26, 1738-45		78

862	QSAR and Molecular Modeling Studies of Factor Xa and Thrombin Inhibitors. 1-53		1
861	Deuterium solvent isotope effect and proton-inventory studies of factor Xa-catalyzed reactions. <i>Biochemistry</i> , 2006 , 45, 14175-82	3,2	6
860	Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. 2006 , 49, 5389-403		80
859	Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. 2006 , 49, 7781-91		59
858	A novel search engine for virtual screening of very large databases. 2006 , 46, 836-43		40
857	Semiempirical Comparative Binding Energy Analysis (SE-COMBINE) of a Series of Trypsin Inhibitors. 2006 , 2, 383-99		29
856	Differential action of proteases from <i>Trimeresurus malabaricus</i> , <i>Naja naja</i> and <i>Daboia russellii</i> venoms on hemostasis. 2006 , 143, 295-302		8
855	Macromolecular substrate affinity for free factor VIIa is independent of a buried protease domain N-terminus. 2006 , 341, 28-32		8
854	Perioperative management of the patient with hematologic disorders. 2006 , 18, 161-71, v		4
853	Gold nanoparticles-based protease assay. 2006 , 103, 3978-82		251
852	A branched pathway governing the activation of a developmental transcription factor by regulated intramembrane proteolysis. 2006 , 23, 25-35		54
851	Expression, purification and characterization of factor IX derivatives using a novel vector system. 2006 , 50, 196-202		9
850	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors V. A series of new derivatives containing a spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one scaffold. 2006 , 54, 1535-44		7
849	Indoline derivatives I: synthesis and factor Xa (FXa) inhibitory activities. 2006 , 54, 163-74		17
848	Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. 2006 , 108, 4045-51		187
847	Structural Calcium (Trypsin, Subtilisin). 2006 ,		
846	Identification of five novel mutations in the factor XI gene (F11) of patients with factor XI deficiency. 2006 , 17, 69-73		14
845	Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor. 2006 , 17, 251-7		28

844	Spherical bioactive glass with enhanced rates of hydroxyapatite deposition and hemostatic activity. 2006 , 2, 1261-5	184
843	Comparative Study of Factor Xa Inhibitors Using Molecular Docking/SVM/HQSAR/3D-QSAR Methods. 2006 , 25, 25-45	6
842	Peptide vector for gene delivery with high affinity for phosphatidylserine. 2006 , 12, 626-32	6
841	Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor. 2006 , 4, 1071-7	34
840	Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. 2006 , 4, 1982-8	94
839	Severe prothrombin deficiency caused by prothrombin-Edmonton (R-4Q) combined with a previously undetected deletion. 2006 , 4, 2623-8	12
838	Approaches to selective peptidic inhibitors of factor Xa. 2006 , 68, 11-9	9
837	Modulation of fibrin cofactor activity in plasminogen activation. 2001 , 936, 247-60	14
836	Genetic manipulation of fibrinogen and fibrinolysis in mice. 2001 , 936, 276-90	24
835	An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. 2006 , 12, 223-7	25
834	Targeting proteases: successes, failures and future prospects. 2006 , 5, 785-99	988
833	Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. 2006 , 25, 2029-37	149
832	Determinants of thrombin specificity. 2001 , 936, 133-46	22
831	Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists. 2006 , 16, 1544-8	20
830	The Na ⁺ binding channel of human coagulation proteases: novel insights on the structure and allosteric modulation revealed by molecular surface analysis. 2006 , 119, 282-94	9
829	Small ubiquitin-like modifying protein isopeptidase assay based on poliovirus RNA polymerase activity. 2006 , 350, 214-21	25
828	Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand. 2006 , 14, 7688-705	15
827	3-Nitrotyrosine as a spectroscopic probe for investigating protein protein interactions. 2006 , 15, 976-86	54

826	Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells. 2006 , 51, 2007-12	13
825	Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. 2006 , 84, 334-44	42
824	Mathematical modeling of material-induced blood plasma coagulation. 2006 , 27, 796-806	45
823	In vitro hemocompatibility testing of UV-modified hyaluronan hydrogels. 2006 , 27, 1416-24	98
822	Membrane-mimetic films containing thrombomodulin and heparin inhibit tissue factor-induced thrombin generation in a flow model. 2006 , 27, 2637-50	36
821	Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure. 2006 , 16, 1032-6	15
820	Procoagulant factors and the risk of myocardial infarction in young women. 2006 , 77, 67-73	50
819	Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. 2006 , 118, 1713-20	40
818	Sources of tissue factor. 2006 , 32, 11-23	164
817	Ca ²⁺ influx induced by protease-activated receptor-1 activates a feed-forward mechanism of TRPC1 expression via nuclear factor-kappaB activation in endothelial cells. 2006 , 281, 20715-20727	49
816	The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation. <i>Biochemistry</i> , 2006 , 45, 10777-85	3.2 19
815	An overview of the structure and function of thrombin. 2006 , 32 Suppl 1, 3-15	175
814	Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. 2006 , 10, 132-42	23
813	Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents. 2006 , 16, 493-505	26
812	High resolution structures of p-aminobenzamidine- and benzamidine-VIIa/soluble tissue factor: unpredicted conformation of the 192-193 peptide bond and mapping of Ca ²⁺ , Mg ²⁺ , Na ⁺ , and Zn ²⁺ sites in factor VIIa. 2006 , 281, 24873-88	67
811	Corrosion resistance and antithrombogenic behavior of La and Nd ion implanted stainless steels. 2006 , 24, 1790-1794	8
810	PROTHROMBIN ACTIVATORS FROM AUSTRALIAN SNAKES. 2006 , 25, 257-290	2
809	Arginine mimetic structures in biologically active antagonists and inhibitors. 2006 , 13, 3627-48	56

808	Anti-hemostatic effects of a serpin from the saliva of the tick <i>Ixodes ricinus</i> . 2006 , 281, 26361-9	96
807	Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. 2006 , 103, 879-84	35
806	Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. 2006 , 281, 32941-5	149
805	Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange. 2006 , 281, 23018-24	47
804	Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. 2006 , 281, 12743-50	85
803	Role of the alpha-helix 163-170 in factor Xa catalytic activity. 2007 , 282, 31569-79	22
802	Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. 2007 , 282, 36714-23	80
801	Hydrogen/deuterium exchange-mass spectrometry: a powerful tool for probing protein structure, dynamics and interactions. 2007 , 14, 2344-58	86
800	Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome. 2007 , 3, 91-98	6
799	Validation of the human tissue factor/FVIIa complex as an antithrombotic target and the discovery of a synthetic peptide. 2007 , 3, 249-62	
798	Heparin binding induces a conformational change in pigment epithelium-derived factor. 2007 , 282, 6661-7	16
797	Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX. 2007 , 282, 15632-44	13
796	Biocompatibility of Cerium Oxide Films Synthesized by Dual Plasma Deposition. 2007 , 330-332, 749-752	1
795	Increased plasma concentrations of antiprothrombin antibodies in women with recurrent spontaneous abortions. 2007 , 53, 228-32	9
794	Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities. 2007 , 55, 1494-504	13
793	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors(1-6) VI. A series of new derivatives containing N,S- and N,SO ₂ -spiro acetal scaffolds. 2007 , 55, 317-23	9
792	Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa. 2007 , 405, 429-38	20
791	FRET studies with factor X mutants provide insight into the topography of the membrane-bound factor X/Xa. 2007 , 407, 427-33	15

790	A novel mutation (Gln433Glu) in exon 12 combined with the G insertion in exon 13 causes severe factor XI deficiency in Japanese patients. 2007 , 18, 519-23	3
789	Mathematical modeling of blood coagulation cascade: kinetics of intrinsic and extrinsic pathways in normal and deficient conditions. 2007 , 18, 637-46	19
788	Protective immunity against <i>Ixodes ricinus</i> induced by a salivary serpin. 2007 , 25, 3284-92	61
787	Characterization of anti-coagulant properties of prenylated coumarin ferulenol. 2007 , 1770, 1437-40	23
786	Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode <i>Ancylostoma caninum</i> . 2007 , 366, 602-10	31
785	Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from <i>Ancylostoma caninum</i> . 2007 , 371, 774-86	21
784	Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists. 2007 , 50, 5147-60	29
783	How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. 2007 , 82, 864-73	228
782	Anticoagulants in heart disease: current status and perspectives. 2007 , 28, 880-913	94
781	Metabolism-based identification of a potent thrombin receptor antagonist. 2007 , 50, 129-38	35
780	Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor. 2007 , 20, 453-63	21
779	Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation. <i>Biochemistry</i> , 2007 , 46, 9830-9	3.2 12
778	[Expression and characterization of fusion protein tTF/SA as a universal effector for targeting blood coagulation]. 2007 , 23, 218-22	
777	Association free energy of dipalmitoylphosphatidylserines in a mixed dipalmitoylphosphatidylcholine membrane. 2007 , 92, 3071-80	15
776	Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human alpha-thrombin. 2007 , 92, 4244-53	38
775	Biophysical characterization of anticoagulant hemexin AB complex from the venom of snake <i>Hemachatus haemachatus</i> . 2007 , 93, 3963-76	17
774	Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick. 2007 , 282, 29101-13	79
773	INTERACTION OF SNAKE-VENOM PROTEINS WITH BLOOD COAGULATION FACTORS: MECHANISMS OF ANTICOAGULANT ACTIVITY. 2007 , 26, 25-46	14

772	Factor Xa inhibitors: S1 binding interactions of a series of N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)sulfonamides. 2007 , 50, 1546-57	42
771	The serine protease corin in cardiovascular biology and disease. 2007 , 12, 4179-90	54
770	Up-regulation of tissue factor in human pulmonary artery endothelial cells after ultrafine particle exposure. 2007 , 115, 535-40	51
769	Calcium-Binding Proteins. 2007 ,	
768	Vascular Regenerative Engineering. 659-735	
767	A second case of prothrombin Puerto Rico I in the United States. 2007 , 82, 661-2	8
766	Co-localization of the channel activating protease prostaticin/(CAP1/PRSS8) with its candidate activator, matriptase. 2007 , 213, 237-45	76
765	Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa. 2007 , 15, 2127-46	22
764	Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors. 2007 , 15, 4175-92	11
763	The influence of biomaterials on endothelial cell thrombogenicity. 2007 , 28, 2547-71	191
762	Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors. 2007 , 17, 5952-8	8
761	Probing the S2 site of factor VIIa to generate potent and selective inhibitors: the structure of BCX-3607 in complex with tissue factor-factor VIIa. 2007 , 63, 689-97	4
760	Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities. 2007 , 33, 376-80	34
759	Seven novel point mutations in the F11 gene in Iranian FXI-deficient patients. 2008 , 14, 91-5	6
758	Quantitative real-time reverse transcription polymerase chain reaction analysis of a novel tissue factor splice variant in select human solid tumors. 2007 , 5, 640-1	4
757	A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect. 2007 , 5, 781-7	11
756	The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. 2007 , 5, 804-11	45
755	The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. 2007 , 5, 1106-12	152

754	Mg(2+) binding to the Gla domain of factor X influences the interaction with tissue factor. 2007 , 5, 1977-8	16
753	Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. 2007 , 1776, 22-31	72
752	Novel compounds directed against the inhibition of protease cascades. 2007 , 12, 1083-1084	
751	Recurrence of a Phe31Ser mutation in the Gla domain of blood coagulation factor X, in unrelated Algerian families: a founder effect?. 2007 , 78, 405-9	8
750	A combined structural dynamics approach identifies a putative switch in factor VIIa employed by tissue factor to initiate blood coagulation. 2007 , 16, 671-82	28
749	Computational study of coagulation factor VIIa's affinity for phospholipid membranes. 2007 , 36, 133-44	7
748	alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis. 2007 , 304, 189-97	1
747	Sulfated polysaccharide purified from <i>Ecklonia cava</i> accelerates antithrombin III-mediated plasma proteinase inhibition. 2007 , 19, 425-430	23
746	A thrombin inhibitor from the gut of <i>Boophilus microplus</i> ticks. 2007 , 42, 291-300	26
745	Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT). 2007 , 166, 427-31	3
744	Cofactor-induced and mutational activity enhancement of coagulation factor VIIa. 2008 , 65, 953-63	17
743	Effect of microgravity on gene expression in mouse brain. 2008 , 191, 289-300	38
742	Structural basis of substrate specificity in the serine proteases. 1995 , 4, 337-60	642
741	Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). 1995 , 4, 740-6	53
740	Polarographic Behavior of Human Plasma Thrombin and Changes in Its Anticoagulation Activity Through Various Conformations. 2008 , 20, 1339-1345	
739	Application of molecular connectivity and electro-topological indices in quantitative structure-activity analysis of pyrazole derivatives as inhibitors of factor Xa and thrombin. 2008 , 5, 2609-20	3
738	Factor XI gene mutations in factor XI deficient patients of the Czech Republic. 2008 , 83, 916-9	5
737	Purification and characterization of a novel anticoagulant peptide from marine echiuroid worm, <i>Urechis unicinctus</i> . 2008 , 43, 179-184	62

736	Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. 2008 , 16, 2243-60	13
735	Design, synthesis, and thrombin-inhibitory activity of pyridin-2-ones as P2/P3 core motifs. 2008 , 18, 1972-6	24
734	Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy. 2008 , 18, 4682-7	5
733	Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination. 2008 , 18, 4533-7	13
732	The thrombogenicity of human umbilical vein endothelial cell seeded collagen modules. 2008 , 29, 2453-63	49
731	A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. 2008 , 9, 602-9	6
730	Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice. 2008 , 6, 306-314	26
729	DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. 2008 , 6, 1542-9	197
728	The multi-functional serpin, protein C inhibitor: beyond thrombosis and hemostasis. 2008 , 6, 2017-26	42
727	The Yin-Yang of thrombin and activated protein C. 2008 , 140, 505-15	26
726	Determination of Kinetic Constants for the Interaction Between the Platelet Glycoprotein IIb-IIIa and Fibrinogen by Means of Surface Plasmon Resonance. 2008 , 227, 647-656	1
725	Stability and binding properties of a modified thrombin binding aptamer. 2008 , 94, 562-9	121
724	The tertiary structure and domain organization of coagulation factor VIII. 2008 , 111, 1240-7	199
723	Thrombin generation determined by calibrated automated thrombography (CAT) in pediatric patients with congenital heart disease. 2008 , 122, 13-9	40
722	Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites. 2008 , 73, 4345-61	86
721	Anti-inflammatory effect of a human prothrombin fragment-2-derived peptide, NSA9, in EOC2 microglia. 2008 , 368, 779-85	16
720	Sequences analysis of mitochondrial tRNA-thr, tRNA-pro and control region from spotted seals (Phoca Largha) in liaodong gulf. 2008 , 136, S529	
719	Purification and characterization of a novel anticoagulant peptide from marine echiuroid worm, Urechis unicinctus. 2008 , 136, S529	

718	Genetic variations analysis for the wild and cultured populations of <i>Paralichthys olivaceus</i> in Dalian sea area by microsatellite markers. 2008 , 136, S529		
717	Blood Coagulation Meter: A Low Cost Viscoelasticity based Approach. 2008 ,		
716	Generic nitric oxide (NO) generating surface by immobilizing organoselenium species via layer-by-layer assembly. 2008 , 24, 10265-72		46
715	Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa. <i>Biochemistry</i> , 2008 , 47, 1326-35	3.2	8
714	Factor Va alters the conformation of the Na ⁺ -binding loop of factor Xa in the prothrombinase complex. <i>Biochemistry</i> , 2008 , 47, 5976-85	3.2	4
713	Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. 2008 , 283, 3031-3041		48
712	Mechanism of the Ca ²⁺ -induced enhancement of the intrinsic factor VIIa activity. 2008 , 283, 25863-70		11
711	Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation. 2008 , 283, 26518-27		41
710	Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. 2008 , 7, 1925-51		120
709	Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. 2008 , 283, 6696-705		28
708	Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. 2008 , 283, 12293-304		101
707	Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). 2008 , 389, 653-68		32
706	Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. 2008 , 102, 457-64		27
705	The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry. 2008 , 283, 13378-87		26
704	Factor V Leiden, prothrombin G20210A, and protein C mutation frequency in Turkish venous thrombosis patients. 2008 , 14, 415-20		14
703	Cinnamyl derivatives: synthesis and factor Xa (FXa) inhibitory activities. 2008 , 56, 758-70		2
702	Pedigree analysis of factor XI deficiency in Japanese black cattle. 2008 , 70, 297-9		9
701	Four novel FXI gene mutations in three factor XI- deficient patients. 2008 , 19, 240-2		2

700	Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography. 2008 , 19, 389-93	
699	Thrombin regulates CD40 expression in microglial cells. 2008 , 19, 757-60	3
698	Anti-human tissue factor antibody ameliorated intestinal ischemia reperfusion-induced acute lung injury in human tissue factor knock-in mice. 2008 , 3, e1527	20
697	COMPUTATIONAL STUDY FOR BINDING OF OSCILLARIN TO HUMAN β THROMBIN. 2009 , 08, 551-560	3
696	ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. 2009 , 284, 30925-32	18
695	A kringle-containing protease with plasminogen-like activity in the basal chordate <i>Branchiostoma belcheri</i> . 2009 , 29, 385-95	47
694	Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: role of microglial NADPH oxidase. 2009 , 214, 83-92	15
693	Scoring ligand similarity in structure-based virtual screening. 2009 , 22, 280-92	23
692	Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. 2010 , 88, 1537-48	27
691	Total synthesis of a unique tetrasaccharide present in the human clotting factor IX and mammalian Notch 1 receptor. 2009 , 20, 473-477	9
690	Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores. 2009 , 17, 3934-58	8
689	Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one. 2009 , 17, 7993-8002	
688	Rheological study on coagulation of blood with special reference to the triggering mechanism of venous thrombus formation. 2009 , 23, 2-10	14
687	Influence of age and hematocrit on the coagulation of blood. 2009 , 23, 111-114	7
686	Complexity in the genetic architecture of leukoaraiosis in hypertensive sibships from the GENOA Study. 2009 , 2, 16	20
685	Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa. 2009 , 276, 3099-109	9
684	Thrombin-mediated impairment of fibroblast growth factor-2 activity. 2009 , 276, 3277-89	2
683	Genetic description of factor XI deficiency in holstein semen in Western Japan. 2009 , 44, 792-6	3

682	Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. 2009 , 7, 1696-702			13
681	Isolation and characterisation of an anticoagulant oligopeptide from blue mussel, <i>Mytilus edulis</i> . 2009 , 117, 687-692			79
680	Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors. 2009 , 19, 4034-41			14
679	Proton bridging in the interactions of thrombin with small inhibitors. <i>Biochemistry</i> , 2009 , 48, 7296-304	3.2		4
678	Mutagenesis studies toward understanding allostery in thrombin. <i>Biochemistry</i> , 2009 , 48, 8261-70	3.2		13
677	Membrane-dependent interaction of factor Xa and prothrombin with factor Va in the prothrombinase complex. <i>Biochemistry</i> , 2009 , 48, 5034-41	3.2		17
676	The influence of different glycosylation patterns on factor VII biological activity. 2009 , 91, 1123-30			9
675	Characterization of porcine factor VII, X and comparison with human factor VII, X. 2009 , 43, 111-8			10
674	Structure-activity relationships of a caged thrombin binding DNA aptamer: insight gained from molecular dynamics simulation studies. 2009 , 166, 241-50			30
673	Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. 2002 , 11, 2091-101			41
672	Perfluorinated Heteroaromatic Systems as Scaffolds for Drug Discovery. 291-311			1
671	Thrombosis and Hemostasis. 2009 , 21-38			1
670	Inhibition of gamma-thrombin-induced human platelet aggregation by histone H1subtypes and H1.3 fragments. 2009 , 20, 349-56			2
669	The role of saliva in tick feeding. 2009 , 14, 2051-88			374
668	Regulation by Covalent Modification. 2009 , 631-678			
667	Barnacle cement: a polymerization model based on evolutionary concepts. 2009 , 212, 3499-510			105
666	The role of tissue factor and factor VIIa in hemostasis. 2009 , 108, 1447-52			218
665	Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles. 2009 , 20, 71-7			5

664	Differential contributions of Glu96, Asp102 and Asp111 to coagulation factor V/Va metal ion binding and subunit stability. 2009 , 422, 257-64	4
663	Factor XI contributes to thrombin generation in the absence of factor XII. 2009 , 114, 452-8	110
662	Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives. 2009 , 57, 22-33	11
661	Molecular diversity of anticoagulants from haematophagous animals. 2009 , 102, 437-53	68
660	The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. 2010 , 116, 1344-51	67
659	Tissue factor and cardiovascular disease: quo vadis?. 2010 , 74, 3-12	87
658	Design and synthesis of peptidomimetic factor VIIa inhibitors. 2010 , 58, 38-44	0
657	Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor. 2010 , 53, 3517-31	36
656	Single-pair fluorescence resonance energy transfer (spFRET) for the high sensitivity analysis of low-abundance proteins using aptamers as molecular recognition elements. 2010 , 20, 203-13	12
655	Factor Xa-like and fibrin(ogen)olytic activities of a serine protease from Hippasa agelenoides spider venom gland extract. 2010 , 29, 119-26	23
654	Substrate Recognition. 2010 , 473-504	
653	Peptide-functionalized spherical polyelectrolyte nanobrushes for real-time sensing of protease activity. 2010 , 11, 494-7	6
652	Quantum Semiempirical Energy Based (SEEB) Descriptors Performance with Benzamidine Inhibitors of Trypsin. 2010 , 29, 525-31	1
651	Characterization of factor VIII pharmaceutical preparations by means of MudPIT proteomic approach. 2010 , 53, 50-7	7
650	Synthesis of a versatile 2 (1H)-pyrazinone core for the preparation of Tissue Factor-Factor VIIa inhibitors. 2010 , 66, 2570-2581	6
649	Hageman factor, platelets and polyphosphates: early history and recent connection. 2010 , 8, 1670-4	45
648	Factor XI deficiency: two novel mutations in asymptomatic Italian patients. 2010 , 16, 767-70	2
647	Purification and Biochemical Characterization of Alkaline Serine Protease from Caesalpinia bonducella. 2010 , 5, 1934578X1000500	

646	Anticoagulation. 2010 , 443-451	1
645	The <i>Drosophila</i> serine protease homologue Scarface regulates JNK signalling in a negative-feedback loop during epithelial morphogenesis. 2010 , 137, 2177-86	29
644	Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. 2010 , 116, 4684-92	140
643	Factor X/Xa elicits protective signaling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment of PAR-1. 2010 , 285, 34803-12	31
642	Effect of covalent antithrombin-heparin on activated protein C inactivation by protein C inhibitor. 2010 , 148, 255-60	3
641	Crystal structure of prethrombin-1. 2010 , 107, 19278-83	32
640	Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa. 2010 , 285, 28488-95	5
639	Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa. 2010 , 285, 20399-409	38
638	A role for factor XIIIa-mediated factor XI activation in thrombus formation in vivo. 2010 , 116, 3981-9	185
637	Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. 2010 , 3, 469-83	28
636	Thrombin mediates severe neurovascular injury during ischemia. 2010 , 41, 2348-52	103
635	Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa. 2010 , 21, 128-34	11
634	Stabilizing of a globular protein by a highly complex water network: a molecular dynamics simulation study on factor Xa. 2010 , 114, 7405-12	49
633	FVII dependent coagulation activation in citrated plasma by polymer hydrogels. 2010 , 11, 3248-55	8
632	A sensitive HIV-1 envelope induced fusion assay identifies fusion enhancement of thrombin. 2010 , 391, 1780-4	4
631	Optically patternable polymer films as model interfaces to study cellular behaviour on topographically structured materials. 2011 , 22, 577-88	1
630	Nanomedicine: swarming towards the target. 2011 , 10, 482-3	41
629	Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation. <i>Biochemistry</i> , 2011 , 50, 10195-202	3-2 37

628	Biomolecule-recognition gating membrane using biomolecular cross-linking and polymer phase transition. 2011 , 83, 9226-9	21
627	Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation. 2011 , 187, 6483-90	38
626	Binding affinities of factor Xa inhibitors estimated by thermodynamic integration and MM/GBSA. 2011 , 51, 947-58	59
625	Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood. 2011 , 100, 23-31	3
624	Nonthrombogenic approaches to cardiovascular bioengineering. 2011 , 13, 451-75	89
623	Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. 2011 , 236, 515-23	86
622	A GRID-derived water network stabilizes molecular dynamics computer simulations of a protease. 2011 , 51, 2860-7	13
621	The effect of GlycoPEGylation on the physical stability of human rFVIIa with increasing calcium chloride concentration. 2011 , 78, 222-8	4
620	Effects on the conformation of FVIIa by sTF and Ca ²⁺ binding: studies of fluorescence resonance energy transfer and quenching. 2011 , 413, 545-9	1
619	Heparin affinity of factor VIIa: implications on the physiological inhibition by antithrombin and clearance of recombinant factor VIIa. 2011 , 127, 154-60	8
618	Perfluoroheteroaromatic Chemistry: Multifunctional Systems from Perfluorinated Heterocycles by Nucleophilic Aromatic Substitution Processes. 2011 , 1-31	3
617	Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. 2011 , 29, e22-35	6
616	A novel missense mutation Asp506Gly in Exon 13 of the F11 gene in an asymptomatic Korean woman with mild factor XI deficiency. 2011 , 31, 290-3	1
615	A network-based multi-target computational estimation scheme for anticoagulant activities of compounds. 2011 , 6, e14774	22
614	Adaptive evolution of the venom-targeted vWF protein in opossums that eat pitvipers. 2011 , 6, e20997	57
613	Microenvironmental geometry guides platelet adhesion and spreading: a quantitative analysis at the single cell level. 2011 , 6, e26437	38
612	Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction. 2011 , 117, 7164-73	10
611	Structural Calcium (Trypsin, Subtilisin). 2011 ,	0

610	Allostery in trypsin-like proteases suggests new therapeutic strategies. 2011 , 29, 577-85	71
609	Ac-AP-12, a novel factor Xa anticoagulant peptide from the esophageal glands of adult <i>Ancylostoma caninum</i> . 2011 , 177, 42-8	18
608	Hypostasis in the heart and great vessels of non-traumatic in-hospital death cases on postmortem computed tomography: relationship to antemortem blood tests. 2011 , 13, 280-5	23
607	Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. 2011 , 32, 9504-14	54
606	Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors. 2011 , 21, 7516-21	12
605	In vitro analysis of polyurethane foam as a topical hemostatic agent. 2011 , 22, 1081-6	14
604	Proteomic analysis of the coagulation reaction in plasma and whole blood using PROTOMAP. 2011 , 11, 2377-88	19
603	Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. 2011 , 31, 202-83	21
602	A challenging system: free energy prediction for factor Xa. 2011 , 32, 1743-52	55
601	A new direction for anticoagulants: inhibiting fibrin assembly with PEGylated fibrin knob mimics. 2011 , 108, 2424-33	14
600	2-aminomethylphenylamine as a novel scaffold for factor Xa inhibitor. 2011 , 19, 1623-42	7
599	Detection of protease activities by flash chronopotentiometry using a reversible polycation-sensitive polymeric membrane electrode. 2011 , 416, 67-73	15
598	Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa. 2011 , 406, 62-8	23
597	The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation. 2011 , 55, 597-602	9
596	Nucleic acid aptamers against proteases. 2011 , 18, 4139-51	21
595	Molecular characterization of FXI deficiency. 2011 , 17, 27-32	11
594	Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. 2011 , 71, 6492-502	70
593	Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons. 2011 , 2011, 476158	32

592	Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. 2011 , 2011, 432080		79
591	Thrombin generation in hemorrhage control and vascular occlusion. 2011 , 124, 225-35		56
590	Protease signalling: the cutting edge. 2012 , 31, 1630-43		203
589	The effects of proton radiation on the prothrombin and partial thromboplastin times of irradiated ferrets. 2012 , 88, 327-34		19
588	Direct thrombin inhibitors. 2012 , 17, 5-11		17
587	Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways. 2012 , 287, 8994-9001		10
586	Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa. 2012 , 287, 6187-95		4
585	A smart hydrogel-based time bomb triggers drug release mediated by pH-jump reaction. 2012 , 13, 064202		19
584	Reactions of 4-substituted tetrafluoropyridine derivatives with sulfur nucleophiles: SNAr and annelation processes. 2012 , 143, 148-154		8
583	PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. 2012 , 14, 35-42		18
582	A four-domain Kunitz-type proteinase inhibitor from <i>Solen grandis</i> is implicated in immune response. 2012 , 33, 1276-84		14
581	Ets-1 transcription is required in tissue factor driven microvessel formation and stabilization. 2012 , 15, 657-69		20
580	Identification of exosite residues of factor Xa involved in recognition of PAR-2 on endothelial cells. <i>Biochemistry</i> , 2012 , 51, 2551-7	3.2	10
579	Factor XI: hemostasis, thrombosis, and antithrombosis. 2012 , 129, 541-50		33
578	Novel molecules for the correction of factor Xa generation and phenotype in hemophilia. 2012 , 129 Suppl 2, S51-3		1
577	Allosteric activation of human β thrombin through exosite 2 by suramin analogs. 2012 , 520, 36-41		1
576	Physiology of Hemostasis. 2012 , 1-19		1
575	Surface chemistry to minimize fouling from blood-based fluids. 2012 , 41, 5599-612		216

574	Protein Surface Interactions and Biocompatibility: A Forty Year Perspective. 2012 , 277-300	
573	Halogenated Heterocycles. 2012 ,	8
572	Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes. 2012 , 7, e36212	30
571	Contribution of the NH ₂ -terminal EGF-domain of factor IXa to the specificity of intrinsic tenase. 2012 , 108, 1154-64	8
570	Prospective Efficacy and Safety of a Novel Bypassing Agent, FVIIa/FX Mixture (MC710) for Hemophilia Patients with Inhibitors. 2012 ,	
569	Antithrombotic and profibrinolytic activities of eckol and dieckol. 2012 , 113, 2877-83	54
568	Ca ²⁺ -induced binding of anticoagulation factor II from the venom of Agkistrodon acutus with factor IX. 2012 , 97, 818-24	1
567	A general method for detecting protease activity via gelation and its application to artificial clotting. 2012 , 48, 5482-4	69
566	Exploration of conformational transition in the aryl-binding site of human FXa using molecular dynamics simulations. 2012 , 18, 2717-25	11
565	From snake venom toxins to therapeutics--cardiovascular examples. 2012 , 59, 497-506	153
564	Anticoagulation factor I, a snake C-type lectin from Agkistrodon acutus venom binds to FIX as well as FX: Ca ²⁺ induced binding data. 2012 , 59, 718-23	16
563	Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation. 2012 , 64, 325-34	60
562	Expression and functional characterization of boophilin, a thrombin inhibitor from Rhipicephalus (Boophilus) microplus midgut. 2012 , 187, 521-8	29
561	The Kazal-type inhibitors infestins 1 and 4 differ in specificity but are similar in three-dimensional structure. 2012 , 68, 695-702	21
560	Determinants of the specificity of protease-activated receptors 1 and 2 signaling by factor Xa and thrombin. 2012 , 113, 977-84	20
559	Amblyomma americanum tick saliva serine protease inhibitor 6 is a cross-class inhibitor of serine proteases and papain-like cysteine proteases that delays plasma clotting and inhibits platelet aggregation. 2013 , 22, 306-19	48
558	A novel protein C inhibitor gene mutation in pediatric stroke patients after bone marrow transplantation. 2013 , 40, 5465-8	0
557	Thrombin. 2013 , 2915-2932	4

556	Antithrombotic and profibrinolytic activities of isorhamnetin-3-O-galactoside and hyperoside. 2013 , 53, 197-204	36
555	In vivo hemostatic efficacy of polyurethane foam compared to collagen and gelatin. 2013 , 17, 1273-8	10
554	Structural characterization of coagulant Moringa oleifera Lectin and its effect on hemostatic parameters. 2013 , 58, 31-6	31
553	Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. 2013 , 112, 12-7	26
552	Shotgun proteomics of coelomic fluid from the purple sea urchin, Strongylocentrotus purpuratus. 2013 , 40, 35-50	23
551	Development of nonstick and drug-loaded wound dressing based on the hydrolytic hydrophobic poly(carboxybetaine) ester analogue. 2013 , 5, 10489-94	36
550	Cytokine profile and FVIII inhibitors development in haemophilia A. 2013 , 19, e139-42	13
549	Production of transgenic goats expressing human coagulation factor IX in the mammary glands after nuclear transfer using transfected fetal fibroblast cells. 2013 , 22, 131-42	26
548	Interleukin-13/Interleukin-4-induced oxidative stress contributes to death of prothrombin-2 (pKr-2)-activated microglia. 2013 , 265, 36-42	21
547	Antithrombotic activities of pellitorine in vitro and in vivo. 2013 , 91, 1-8	11
546	Molecular cloning, characterization and expression analysis of coagulation factor VII gene in grass carp (Ctenopharyngodon idella). 2013 , 35, 618-22	3
545	Proton bridging in the interactions of thrombin with hirudin and its mimics. <i>Biochemistry</i> , 2013 , 52, 2472-31	2
544	Deorphanization and target validation of cross-tick species conserved novel Amblyomma americanum tick saliva protein. 2013 , 43, 439-51	41
543	General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. 2013 , 109, 569-79	134
542	Anticoagulant activities of persicarin and isorhamnetin. 2013 , 58, 272-9	16
541	Bio-inspired liposomal thrombomodulin conjugate through bio-orthogonal chemistry. 2013 , 24, 550-9	18
540	Ultrasensitive surface-enhanced Raman scattering detection of trypsin based on anti-aggregation of 4-mercaptopyridine-functionalized silver nanoparticles: an optical sensing platform toward proteases. 2013 , 5, 5905-11	73
539	Molecular characterization of two kazal-type serine proteinase inhibitor genes in the surf clam Mesodesma donacium exposed to Vibrio anguillarum. 2013 , 34, 1448-54	18

538	Proteases in Blood Clotting. 2013 , 585-589	1
537	Protein anticoagulants targeting factor VIIa-tissue factor complex: a comprehensive review. 2013 , 18, 1-7	2
536	Reversible regulation of aptamer activity with effector-responsive hairpin oligonucleotides. 2013 , 18, 77-84	1
535	Biocompatibility of implantable systems. 2013 , 215-252	1
534	Cleavage entropy as quantitative measure of protease specificity. 2013 , 9, e1003007	41
533	A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency. 2013 , 24, 670-2	1
532	Autoactivation of thrombin precursors. 2013 , 288, 11601-10	32
531	Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa. 2013 , 288, 12692-8	5
530	Antithrombotic activities of epi-sesamin in vitro and in vivo. 2013 , 41, 1313-27	6
529	Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. 2013 , 33, 1670-8	95
528	Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. 2013 , 110, 1065-73	24
527	[Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis]. 2013 , 133, 1079-85	4
526	Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets. 2013 , 109, 1016-24	3
525	Gene-centric association signals for haemostasis and thrombosis traits identified with the HumanCVD BeadChip. 2013 , 110, 995-1003	7
524	Real-time electrical impedimetric monitoring of blood coagulation process under temperature and hematocrit variations conducted in a microfluidic chip. 2013 , 8, e76243	37
523	Regulation of vascular function on posttranscriptional level. 2013 , 2013, 948765	13
522	Anticoagulant activities of piperlonguminine in vitro and in vivo. 2013 , 46, 484-9	11
521	Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model. 2014 , 9, e107113	9

520	Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo. 2014 , 47, 376-81	31
519	. 2014 ,	15
518	Thrombin. 2014 ,	
517	Balancing the risk of complications in foot and ankle surgical patients taking antithrombotic medication. 2014 , 7, 507-14	3
516	Immunomodulating effects and hypersensitivity reactions caused by Northeast Indian black fly salivary gland extract. 2014 , 11, 126-32	7
515	Biocompatible Coating. 2014 , 425-447	3
514	New insights into the role of erythrocytes in thrombus formation. 2014 , 40, 72-80	23
513	The linker connecting the two kringles plays a key role in prothrombin activation. 2014 , 111, 7630-5	29
512	The concentrations of EGFR, LRG1, ITIH4, and F5 in serum correlate with the number of colonic adenomas in ApcPirc/+ rats. 2014 , 7, 1160-9	11
511	Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity. 2014 , 57, 9915-32	30
510	The length of the linker between the epidermal growth factor-like domains in factor VIIa is critical for a productive interaction with tissue factor. 2014 , 23, 1717-27	5
509	Effect of Electronic Polarization to Human α Thrombin. 2014 , 31, 048701	3
508	Sites involved in intra- and interdomain allostery associated with the activation of factor VIIa pinpointed by hydrogen-deuterium exchange and electron transfer dissociation mass spectrometry. 2014 , 289, 35388-96	20
507	Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency. 2014 , 100, 345-52	2
506	Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases. 2014 , 2014, 865732	8
505	Blood-aggregating hydrogel particles for use as a hemostatic agent. 2014 , 10, 701-8	109
504	Essential role of conformational selection in ligand binding. 2014 , 186, 13-21	82
503	On the non-linear attachment characteristics of blood to bacterial cellulose/kaolin biomaterials. 2014 , 116, 176-82	14

502	Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician. 2014 , 37, 234-41		6
501	Aeruginosins as Thrombin Inhibitors. 2014 , 333-364		
500	Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A. 2014 , 60, 120-6		18
499	Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. 2014 , 37, 1454-63		45
498	Process-scale purification and analytical characterization of highly gamma-carboxylated recombinant human prothrombin. 2014 , 1325, 171-8		5
497	Label-free fluorescence assay for thrombin based on unmodified quantum dots. 2014 , 54, 42-7		28
496	An update on recent patents on thrombin inhibitors (2010 - 2013). 2014 , 24, 47-67		13
495	The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery. 2014 , 11, 1795-813		17
494	Molecular dynamics characterization of five pathogenic Factor X mutants associated with decreased catalytic activity. <i>Biochemistry</i> , 2014 , 53, 6992-7001	3.2	13
493	Targeting the GPIIb/IIIa binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects. 2014 , 57, 3030-9		19
492	Adjustable bioadhesive control of PEGylated hyperbranch brushes on polystyrene microplate interface for the improved sensitivity of human blood typing. 2014 , 30, 9139-46		13
491	Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study. 2014 , 452, 408-14		16
490	Interventions for the prevention of dry socket: an evidence-based update. 2014 , 217, 27-30		13
489	Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation. 2014 , 98, 27-35		32
488	Antiplatelet, anticoagulant, and profibrinolytic activities of cudraticusxanthone A. 2014 , 37, 1069-78		22
487	A 24-48 h fed <i>Amblyomma americanum</i> tick saliva immuno-proteome. 2014 , 15, 518		74
486	Proteins, platelets, and blood coagulation at biomaterial interfaces. 2014 , 124, 49-68		212
485	MicroRNA-19b functions as potential anti-thrombotic protector in patients with unstable angina by targeting tissue factor. 2014 , 75, 49-57		52

484	Antithrombotic activities of oroxylin A in vitro and in vivo. 2014 , 37, 679-86	18
483	FRET-based and other fluorescent proteinase probes. 2014 , 9, 266-81	39
482	Increasing transcriptome response of serpins during the ontogenetic stages in the salmon louse <i>Caligus rogercresseyi</i> (Copepoda: Caligidae). 2014 , 15, 55-64	9
481	Biological Effects of Space Radiation and Development of Effective Countermeasures. 2014 , 1, 10-43	108
480	Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. 2014 , 133, 799-803	26
479	Role of hydrophobic mutations on the binding affinity and stability of blood coagulation factor VIIIa: a computational molecular dynamics and free-energy analysis. 2014 , 450, 735-40	3
478	Ensemble-based docking using biased molecular dynamics. 2014 , 54, 2127-38	47
477	Evaluation and management of congenital bleeding disorders. 2014 , 32, 673-90	7
476	Potential drug interaction between warfarin and linezolid. 2015 , 54, 459-64	11
475	A biochemical network can control formation of a synthetic material by sensing numerous specific stimuli. 2015 , 5, 10274	7
474	Antithrombotic and antiplatelet activities of vicenin-2. 2015 , 26, 628-34	9
473	Inhibition of thrombin generation in human plasma by phospholipid transfer protein. 2015 , 13, 24	6
472	Evaluation of Serine Protease Inhibitors as Potent FVIIa-sTF Inhibitors in the Blood Coagulation Cascade. 2015 , 13, 3-23	5
471	Biosensing with Förster Resonance Energy Transfer Coupling between Fluorophores and Nanocarbon Allotropes. 2015 , 15, 14766-87	27
470	Preventive Effect of Aspirin Eugenol Ester on Thrombosis in β -Carrageenan-Induced Rat Tail Thrombosis Model. 2015 , 10, e0133125	34
469	Blood coagulation factor VII; structure, function and clinical application. 2015 , 26, 562-575	
468	Protective effects of thrombomodulin on microvascular permeability after subarachnoid hemorrhage in mouse model. 2015 , 299, 18-27	21
467	Inflammatory response and extracorporeal circulation. 2015 , 29, 113-23	40

466	A length bias corrected likelihood ratio test for the detection of differentially expressed pathways in RNA-Seq data. 2015 ,	4
465	Reversing Antisense Oligonucleotide Activity with a Sense Oligonucleotide Antidote: Proof of Concept Targeting Prothrombin. 2015 , 25, 297-305	8
464	pH-metric chemical speciation modeling and studies of in vitro antidiabetic effects of bis[(imidazolyl)carboxylato]oxidovanadium(IV) complexes. 2015 , 145, 11-8	13
463	Virtual screening using combinatorial cyclic peptide libraries reveals protein interfaces readily targetable by cyclic peptides. 2015 , 55, 600-13	9
462	Activity of coagulation factor XI in patients with spontaneous miscarriage: the presence of risk alleles. 2015 , 35, 621-4	4
461	Heixuedian (heix), a potential melanotic tumor suppressor gene, exhibits specific spatial and temporal expression pattern during <i>Drosophila</i> hematopoiesis. 2015 , 398, 218-30	7
460	Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa. 2015 , 38, 1080-9	33
459	Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. 2015 , 23, 257-65	5
458	High-yield preparation of recombinant human ϵ thrombin for therapeutic use. 2015 , 120, 432-7	2
457	The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors. 2015 , 15, 1	9
456	[Kallikrein-Kinin System. Long History and Present. (To 90th Anniversary of Discovery of the System)]. 2015 , 41, 275-91	8
455	Factor B Is the Second Lipopolysaccharide-binding Protease Zymogen in the Horseshoe Crab Coagulation Cascade. 2015 , 290, 19379-86	12
454	Conserved <i>Amblyomma americanum</i> tick Serpin19, an inhibitor of blood clotting factors Xa and XIa, trypsin and plasmin, has anti-haemostatic functions. 2015 , 45, 613-27	41
453	Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients. <i>Biochemistry</i> , 2015 , 54, 3814-21	3.2 1
452	A homolog of Kunitz-type serine protease inhibitor from rock bream, <i>Oplegnathus fasciatus</i> : Molecular insights and transcriptional modulation in response to microbial and PAMP stimulation, and tissue injury. 2015 , 46, 285-91	4
451	Antithrombotic and antiplatelet activities of orientin in vitro and in vivo. 2015 , 17, 388-398	18
450	Automatic and integrated micro-enzyme assay (AIEA) platform for highly sensitive thrombin analysis via an engineered fluorescence protein-functionalized monolithic capillary column. 2015 , 87, 4552-9	19
449	Role of high shear rate in thrombosis. 2015 , 61, 1068-80	131

448	The spectrum of thrombin in acute coronary syndromes. 2015 , 135, 782-7	7
447	Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion. 2015 , 38, 1707-26	19
446	Quantifying vitamin K-dependent holoprotein compaction caused by differential β -carboxylation using high-pressure size exclusion chromatography. 2015 , 479, 6-14	2
445	Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors. 2015 , 96, 369-80	11
444	Peptide self-assembly triggered by metal ions. 2015 , 44, 5200-19	171
443	Synthesis and characterization of fast-swelling porous superabsorbent hydrogel based on starch as a hemostatic agent. 2015 , 26, 1439-51	19
442	Regulation of Instant Blood Mediated Inflammatory Reaction (IBMIR) in Pancreatic Islet Xeno-Transplantation: Points for Therapeutic Interventions. 2015 , 865, 171-88	19
441	Surface immobilization of a protease through an inhibitor-derived affinity ligand: a bioactive surface with defensive properties against an inhibitor. 2015 , 51, 14263-6	8
440	Immune Responses to Biosurfaces. 2015 ,	4
439	Thromboelastography: A Practice Summary for Nurse Practitioners Treating Hemorrhage. 2015 , 11, 702-709	13
438	Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. 2015 , 88, 95-105	18
437	Biocompatible Star Block Copolymer Hydrogel Cross-linked with Calcium Ions. 2015 , 1, 914-918	16
436	A regenerable electrochemiluminescence aptasensor incorporating poly(ethylenimine) and thiosemicarbazide as dual co-reactants for signal amplification. 2015 , 186, 174-181	6
435	A potential Kazal-type serine protease inhibitor involves in kinetics of protease inhibition and bacteriostatic activity. 2015 , 42, 430-8	15
434	Optical Thromboelastography to evaluate whole blood coagulation. 2015 , 8, 372-81	23
433	Inhibitory Effect of FXa on Secretory Group IIA Phospholipase A2. 2015 , 38, 987-94	0
432	Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin. 2015 , 38, 893-903	60
431	Monitoring coagulation proteins during progression of liver disease. 2015 , 30, 210-6	3

430 Viruses Responsible for Hemorrhagic Fevers. **2016**, 161-181

429 The Importance of Thrombin in Cerebral Injury and Disease. **2016**, 17, 72

428 Determination of FVIIa-STF Inhibitors in Toxic Microcystis Cyanobacteria by LC-MS Technique. **2015**, 14, 7 4

427 Aptamer and PNIPAAm co-conjugated nanoparticles regulate activity of enzyme with different temperature. **2016**, 159, 47-54 9

426 Antithrombotic and cytotoxic activities of four Bangladeshi plants and PASS prediction of their isolated compounds. **2016**, 27, 659-666 4

425 Identification and functional characterization of a novel antistasin/WAP-like serine protease inhibitor from the tropical sea cucumber, Stichopus monotuberculatus. **2016**, 59, 203-212 3

424 Monitoring of thrombus formation in mock extracorporeal circulation system using electrical impedance spectroscopy. **2016**, 0

423 Blood flow and mass transfer regulation of coagulation. **2016**, 30, 357-68 29

422 Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition. **2016**, 5, 497-511

421 Structural control and hemostatic properties of porous microspheres fabricated by hydroxyapatite-graft-poly(D,L-lactide) nanocomposites. **2016**, 134, 234-241 9

420 Design and development of potent and selective factor IXa inhibitors. **2016**, 68, 130-135 1

419 Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. **2016**, 128, 1870-1878 30

418 Biomimetic strategies for targeted nanoparticle delivery. **2016**, 1, 30-46 89

417 Hemostasis biomarkers and risk of sepsis: the REGARDS cohort. **2016**, 14, 2169-2176 6

416 Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site. **2016**, 473, 2395-411 7

415 Effects of ezetimibe and anticoagulant combined therapy on progressing stroke: a randomized, placebo-controlled study. **2016**, 263, 2438-2445 3

414 SERS determination of protease through a particle-on-a-film configuration constructed by electrostatic assembly in an enzymatic hydrolysis reaction. **2016**, 6, 90120-90125 12

413 Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X. **2016**, 127, 778-86 8

4 ¹²	Polymerization Initiated by Particle Contact: A Quiescent State Trigger for Materials Synthesis. 2016 , 138, 12336-9	4
4 ¹¹	Uncovering Large-Scale Conformational Change in Molecular Dynamics without Prior Knowledge. 2016 , 12, 6130-6146	26
4 ¹⁰	Soluble P-selectin rescues viper venom-induced mortality through anti-inflammatory properties and PSGL-1 pathway-mediated correction of hemostasis. 2016 , 6, 35868	13
4 ⁰⁹	Reaction mechanism of blood coagulation factors in shear flow field. 2016 , 2016, 4309-4312	
4 ⁰⁸	Antithrombotic and antiplatelet activities of small-molecule alkaloids from <i>Scolopendra subspinipes mutilans</i> . 2016 , 6, 21956	25
4 ⁰⁷	Large-scale molecular dynamics simulation: Effect of polarization on thrombin-ligand binding energy. 2016 , 6, 31488	44
4 ⁰⁶	Synthesis of superabsorbent hydrogel nanocomposites for use as hemostatic agent. 2016 , 65, 779-788	4
4 ⁰⁵	Behavior of plastic and metal ameroid constrictors during in vitro incubation in physiologic solutions of varying glucose concentration. 2016 , 105, 165-70	5
4 ⁰⁴	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. 2016 , 121, 671-698	28
4 ⁰³	Design, Synthesis and Evaluation of Antibacterial Effects of a New Class of Piperazinylquinolone Derivatives. 2016 , 53, 89-94	8
4 ⁰²	New Therapeutic Agents in Thrombosis and Thrombolysis. 2016 ,	6
4 ⁰¹	Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro. 2016 , 39, 398-408	23
4 ⁰⁰	Fluorescent aptamer-based assay for thrombin with large signal amplification using peroxidase mimetics. 2016 , 183, 765-771	16
399	Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection. 2016 , 105, 398-410	21
398	Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity. 2016 , 291, 4671-83	13
397	Discovery of Novel Nonactive Site Inhibitors of the Prothrombinase Enzyme Complex. 2016 , 56, 535-47	12
396	Point-of-care diagnostics for niche applications. 2016 , 34, 161-76	37
395	Coagulation factor II from rock bream (<i>Oplegnathus fasciatus</i>): First report on the molecular biological function and expression analysis in the teleost. 2016 , 48, 145-53	4

394	A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation. 2016 , 141, 77-83	12
393	Quantitative Correlation of Conformational Binding Enthalpy with Substrate Specificity of Serine Proteases. 2016 , 120, 299-308	4
392	Characterization and structural analysis of a potent anticoagulant phospholipase A2 from <i>Pseudechis australis</i> snake venom. 2016 , 111, 37-49	8
391	Mechanisms of Thrombosis and Thrombolysis. 2016 , 13-27	
390	An ultra-sensitive and label-free fluorescent probe for trypsin and inhibitor based on DNA hosted Cu nanoclusters. 2016 , 222, 945-951	28
389	Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. 2017 , 32, 47-54	9
388	FVIIa prevents the progressive hemorrhaging of a brain contusion by protecting microvessels via formation of the TF-FVIIa-FXa complex. 2017 , 348, 114-125	10
387	Expression and characterization of haemathrins, madanin-like thrombin inhibitors, isolated from the salivary gland of tick <i>Haemaphysalis bispinosa</i> (Acari: Ixodidae). 2017 , 152, 20-29	11
386	A Mendelian randomization study of the effect of calcium on coronary artery disease, myocardial infarction and their risk factors. 2017 , 7, 42691	21
385	Thrombin-Mediated Degradation of Human Cardiac Troponin T. 2017 , 63, 1094-1100	42
384	Effects of Cross-Linking Density on Interfacial Polymerization and Scaffold Formation in Functionalized Polymer Beads. 2017 , 56, 4883-4886	7
383	Thrombus Formation at High Shear Rates. 2017 , 19, 415-433	52
382	Silver triangular nanoplates as an high efficiently FRET donor-acceptor of upconversion nanoparticles for ultrasensitive "Turn on-off" protamine and trypsin sensor. 2017 , 174, 148-155	25
381	Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway. 2017 , 130, 666-676	16
380	Perovskite quantum dots encapsulated in electrospun fiber membranes as multifunctional supersensitive sensors for biomolecules, metal ions and pH. 2017 , 2, 225-232	57
379	Histopathological changes and transcriptional alterations of three coagulation factors in zebrafish (<i>Danio rerio</i>) following short-term exposure to MC-LR. 2017 , 37, 120-124	6
378	Determination of structural and thermodynamic parameters of bovine α -trypsin isoform in aqueous-organic media. 2017 , 101, 408-416	3
377	A Computational Model of the Biochemomechanics of an Evolving Occlusive Thrombus. 2017 , 129, 125-144	14

376	Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion. 2017 , 32, 313-323	47
375	Industrial-scale processing of activated platelet-rich plasma from specific pathogen-free pigs and its effect on promoting human hair follicle dermal papilla cell cultivation. 2017 , 71, 28-37	7
374	Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor. 2017 , 7, 14862	6
373	Evaluation and Management of Congenital Bleeding Disorders. 2017 , 31, 1105-1122	2
372	Direct detection of fibrinogen in human plasma using electric-double-layer gated AlGa _N /Ga _N high electron mobility transistors. 2017 , 111, 082106	7
371	Lipid specificity of the membrane binding domain of coagulation factor X. 2017 , 15, 2005-2016	17
370	Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies. 2017 , 280, 159-170	57
369	Factor VII Tokushima (Cys22->Gly) is not β -carboxylated due to a disrupted β -carboxylase recognition site. 2017 , 158, 108-112	2
368	Development, validation, and clinical pharmacokinetic application of ultra-performance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative (Neorudin) and its active metabolite in human serum. 2017 , 1063, 204-213	4
367	Spellbinding Effects of the Acidic COOH-Terminus of Factor Va Heavy Chain on Prothrombinase Activity and Function. 2017 , 2, 5529-5537	1
366	Biomarkers for Vitamin Status and Deficiency. 2017 , 331-345	
365	Novel application of fluorescence coupled capillary electrophoresis to resolve the interaction between the G-quadruplex aptamer and thrombin. 2017 , 40, 3161-3167	7
364	Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. 2017 , 1, 93-102	8
363	Factor 11 single-nucleotide variants in women with heavy menstrual bleeding. 2017 , 37, 912-918	1
362	Preparation and evaluation of chitosan/alginate porous microspheres/Bletilla striata polysaccharide composite hemostatic sponges. 2017 , 174, 432-442	80
361	Cole-Cole analysis of thrombus formation in an extracorporeal blood flow circulation using electrical measurement. 2017 , 53, 172-179	9
360	Acquired Inhibitors to Multiple Coagulation Factors (V, IX, and XII) Identified in a Unique Patient with Hepatocellular Carcinoma. 2017 , 56, 1203-1206	1
359	Bioactive Nanocomposites for Tissue Repair and Regeneration: A Review. 2017 , 14,	61

358	Polysaccharide Fabrication Platforms and Biocompatibility Assessment as Candidate Wound Dressing Materials. 2017 , 4,	90
357	Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders. 2017 , 6,	37
356	FVIIa-STF and Thrombin Inhibitory Activities of Compounds Isolated from <i>Microcystis aeruginosa</i> K-139. 2017 , 15,	3
355	Effect of <i>Clostridium perfringens</i> α -Toxin on Platelets. 2017 , 9,	6
354	Engineering Blood and Lymphatic Microvascular Networks in Fibrin Matrices. 2017 , 5, 25	48
353	Isolation, Characterization and Evaluation of Collagen from Jellyfish <i>Rhopilema esculentum</i> Kishinouye for Use in Hemostatic Applications. 2017 , 12, e0169731	69
352	Determinants of Macromolecular Specificity from Proteomics-Derived Peptide Substrate Data. 2017 , 18, 905-913	0
351	Tetrahydroisoquinolines. 2018 , 356-413	1
350	2-(Hetero)Arylindoles. 2018 , 321-355	2
349	Recombinant batroxobin-coated nonwoven chitosan as hemostatic dressing for initial hemorrhage control. 2018 , 113, 757-763	11
348	Synthesis of Phosphatidylserine and Its Stereoisomers: Their Role in Activation of Blood Coagulation. 2018 , 9, 434-439	6
347	A functional and thromboelastometric-based micromethod for assessing crotoxin anticoagulant activity and antiserum relative potency against <i>Crotalus durissus terrificus</i> venom. 2018 , 148, 26-32	3
346	Coupled Mutations-Enabled Glycerol Transportation in an Aquaporin Z Mutant. 2018 , 3, 4113-4122	2
345	Protein-induced fluorescence enhancement as aptamer sensing mechanism for thrombin detection. 2018 , 267, 294-301	31
344	Evolutionary conservation of the allosteric activation of factor VIIa by tissue factor in lamprey. 2018 , 16, 734-748	3
343	Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI. 2018 , 118, 340-350	5
342	The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. 2018 , 146, 299-317	8
341	Nanoengineered injectable hydrogels for wound healing application. 2018 , 70, 35-47	121

340	Small size fullerene nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa. 2018 , 14, 929-939	15
339	Comparing coagulation activity of <i>Selaginella tamariscina</i> before and after stir-frying process and determining the possible active constituents based on compositional variation. 2018 , 56, 67-75	5
338	The Evolving Role of MicroRNAs in Endothelial Cell Dysfunction in Response to Infection. 2018 , 44, 216-223	4
337	Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. 2018 ,	7
336	Influence of dynamic flow conditions on adsorbed plasma protein corona and surface-induced thrombus generation on antifouling brushes. 2018 , 166, 79-95	24
335	Synthesis, characterization, molecular docking evaluation, antiplatelet and anticoagulant actions of 1,2,4 triazole hydrazone and sulphonamide novel derivatives. 2018 , 12, 11	19
334	Structural modulation of factor VIIa by full-length tissue factor (TF): implication of novel interactions between EGF2 domain and TF. 2018 , 36, 621-633	16
333	Different chemical groups modification on the surface of chitosan nonwoven dressing and the hemostatic properties. 2018 , 107, 463-469	29
332	Overview of Anticoagulation Agents. 2018 , 275-289	
331	Visualizing correlated motion with HDBSCAN clustering. 2018 , 27, 62-75	7
330	Identification and inhibitory activity against α -thrombin of a novel anticoagulant peptide derived from oyster (<i>Crassostrea gigas</i>) protein. 2018 , 9, 6391-6400	16
329	The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index. 2018 , 13, e0206376	7
328	First Report of Plant-Derived β -Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model. 2018 , 81, 2521-2530	9
327	Nanotechnology-enabled materials for hemostatic and anti-infection treatments in orthopedic surgery. 2018 , 13, 8325-8338	18
326	Synthesis, characterization, molecular docking, analgesic, antiplatelet and anticoagulant effects of dibenzylidene ketone derivatives. 2018 , 12, 134	2
325	Oxidative Stress and Neonatal Respiratory Extracorporeal Membrane Oxygenation. 2018 , 9, 1739	9
324	Phase-plane geometries in coupled enzyme assays. 2018 , 306, 126-135	3
323	Therapeutic Potential of Brazilian Cerrado Species on Metabolic Dysfunctions. 2018 , 23,	10

322	Blood compatibility of nanomaterials. 2018 , 13-31	3
321	Kunitz-type serine protease inhibitor is a novel participator in anti-bacterial and anti-inflammatory responses in Japanese flounder (<i>Paralichthys olivaceus</i>). 2018 , 80, 22-30	7
320	A novel three-fluorophore system as a ratiometric sensor for multiple protease detection. 2018 , 54, 7589-7592	15
319	Toxins Are an Excellent Source of Therapeutic Agents against Cardiovascular Diseases. 2018 , 44, 691-706	15
318	Identification and In Silico Prediction of Anticoagulant Peptides from the Enzymatic Hydrolysates of Proteins. 2018 , 19,	12
317	Autocatalytic Cycles in a Copper-Catalyzed Azide-Alkyne Cycloaddition Reaction. 2018 , 140, 10221-10232	37
316	Intermolecular autocatalytic activation of serine protease zymogen factor C through an active transition state responding to lipopolysaccharide. 2018 , 293, 11589-11599	9
315	Homologous Lympho-Epithelial Kazal-type Inhibitor Domains Delay Blood Coagulation by Inhibiting Factor X and XI with Differential Specificity. 2018 , 26, 1178-1186.e3	3
314	Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development. 2018 , 7, e1701461	112
313	Biochemical and histological evidence of deteriorated bioprosthetic valve leaflets: the accumulation of fibrinogen and plasminogen. 2018 , 7,	13
312	BjSP, a novel serine protease from Bothrops jararaca snake venom that degrades fibrinogen without forming fibrin clots. 2018 , 357, 50-61	9
311	Voltammetric aptasensor for thrombin by using a gold microelectrode modified with graphene oxide decorated with silver nanoparticles. 2018 , 185, 407	8
310	An Efficient Surface Modification Strategy Improving Endothelialization with Polydopamine Nanoparticles and REDV Peptides for Stent-Grafts.. 2019 , 2, 3820-3827	1
309	Properties of interpenetrating polymer networks associating fibrin and silk fibroin networks obtained by a double enzymatic method. 2019 , 104, 109931	5
308	Development of in vitro assays for hematotoxic activity of the Russell's viper <i>Daboia siamensis</i> venom. 2019 ,	
307	Tranexamic acid reduces heme cytotoxicity via the TLR4/TNF axis and ameliorates functional recovery after spinal cord injury. 2019 , 16, 160	11
306	Pricing and Incentive Strategy for Green Building Supply Chain with Incentive Mechanism. 2019 , 304, 032111	1
305	Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism. 2019 , 3, 412-419	

304	Effect of tannic acid on blood components and functions. 2019 , 184, 110505	13
303	Intracerebral Hemorrhage: Blood Components and Neurotoxicity. 2019 , 9,	18
302	Antithrombotic and Antiplatelet Activities of New Isohopane Triterpene From the Roots of Rubia akane. 2019 , 14, 1934578X1986291	1
301	Inflammatory Response and Endothelial Dysfunction Following Cardiopulmonary Bypass: Pathophysiology and Pharmacological Targets. 2019 , 13, 158-173	28
300	Implications for maintaining vascular access device patency and performance: Application of science to practice. 2019 , 20, 461-470	3
299	Oral Manifestations of Systemic Diseases and Their Treatments. 2019 , 1523-1639	
298	Interleukin-4 and Interleukin-13 Exacerbate Neurotoxicity of Prothrombin Kringle-2 in Cortex In Vivo via Oxidative Stress. 2019 , 20,	15
297	Advances in the prevention and management of central-line-associated bloodstream infections: The role of chelator-based catheter locks. 2019 , 40, 1036-1045	1
296	The central role of thrombin in bleeding disorders. 2019 , 38, 100582	37
295	Construction of Hemocompatible and Histocompatible Surface by Grafting Antithrombotic Peptide ACH and Hydrophilic PEG. 2019 , 5, 2846-2857	10
294	An unexpected dynamic binding mode between coagulation factor X and Rivaroxaban reveals importance of flexibility in drug binding. 2019 , 94, 1664-1671	1
293	Probing prothrombin structure by limited proteolysis. 2019 , 9, 6125	4
292	Allostery in Coagulation Factor VIIa Revealed by Ensemble Refinement of Crystallographic Structures. 2019 , 116, 1823-1835	3
291	Clopidogrel eluting electrospun polyurethane/polyethylene glycol thromboresistant, hemocompatible nanofibrous scaffolds. 2019 , 33, 1327-1347	18
290	Elevated plasma levels of hepatocyte growth factor in rats experimentally envenomated with Bothrops jararaca venom: Role of snake venom metalloproteases. 2019 , 162, 9-14	6
289	New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. 2019 , 133, 885-904	27
288	2D Nanoclay for Biomedical Applications: Regenerative Medicine, Therapeutic Delivery, and Additive Manufacturing. 2019 , 31, e1900332	133
287	The Disulfide Bond between Cys22 and Cys27 in the Protease Domain Modulate Clotting Activity of Coagulation Factor X. 2019 , 119, 871-881	3

- 286 Platelet-rich clots as identified by Martius Scarlet Blue staining are isodense on NCCT. **2019**, 11, 1145-1149 31
- 285 Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study. **2019**, 17, 574-584 7
- 284 Food-derived antithrombotic peptides: Preparation, identification, and interactions with thrombin. **2019**, 59, S81-S95 24
- 283 Occlusive thrombosis in arteries. **2019**, 3, 041502 21
- 282 Recent advances in computational modeling of fibrin clot formation: A review. **2019**, 83, 107148 15
- 281 Cloning of six serpin genes and their responses to GCRV infection in grass carp (*Ctenopharyngodon idella*). **2019**, 86, 93-100 7
- 280 Sirtilins - the new old members of the vitamin K-dependent coagulation factor family. **2019**, 17, 470-481 6
- 279 Anticoagulation. **2019**, 368-378.e2 1
- 278 HSC70 from *Haemaphysalis flava* (Acari: Ixodidae) exerts anticoagulation activity in vitro. **2019**, 10, 170-175 5
- 277 Rigorous Free Energy Perturbation Approach to Estimating Relative Binding Affinities between Ligands with Multiple Protonation and Tautomeric States. **2019**, 15, 424-435 20
- 276 Biofunctionalized Electrospun PCL-PIBMD/SF Vascular Grafts with PEG and Cell-Adhesive Peptides for Endothelialization. **2019**, 19, e1800386 26
- 275 The Perioperative Management of Partial Knee Arthroplasty: Anesthesia, Pain Management, and Blood Loss. **2019**, 11-18
- 274 Contribution of allosteric disulfide in the structural regulation of membrane-bound tissue factor-factor VIIa binary complex. **2019**, 37, 3707-3720 2
- 273 Antimicrobial Peptide Cathelicidin-BF Inhibits Platelet Aggregation by Blocking Protease-Activated Receptor 4. **2019**, 25, 349-358 4
- 272 Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency. **2020**, 105, 829-837 7
- 271 The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. **2020**, 18, 57-69 9
- 270 Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. **2020**, 1873, 188331 5
- 269 Transferrin plays a central role in coagulation balance by interacting with clotting factors. **2020**, 30, 119-132 21

268	The role of exogenous Fibrinogen in cardiac surgery: stop bleeding or induce cardiovascular disease. 2020 , 47, 8189-8198	7
267	Capillary cell-type specialization in the alveolus. 2020 , 586, 785-789	69
266	Point-of-Care Diagnostics in Coagulation Management. 2020 , 20,	6
265	Antithrombin III-mediated blood coagulation inhibitory activity of chitosan sulfate derivatized with different functional groups. 2020 , 161, 1552-1558	2
264	Platelets as Mediators of Neuroinflammation and Thrombosis. 2020 , 11, 548631	18
263	Phosphatidylethanolamine-phosphatidylserine binding synergy of seven coagulation factors revealed using Nanodisc arrays on silicon photonic sensors. 2020 , 10, 17407	3
262	Marine Collagen as a Source of Biomaterial. 2020 , 1175-1193	0
261	Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. 2020 , 20, 525-533	10
260	Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion. 2020 ,	
259	Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. 2020 , 12, e11298	13
258	Exosites expedite blood coagulation. 2020 , 295, 15208-15209	
257	How Good is Jarzynski's Equality for Computer-Aided Drug Design?. 2020 , 124, 5338-5349	4
256	A novel thrombin inhibitory peptide discovered from leech using affinity chromatography combined with ultra-high performance liquid chromatography-high resolution mass spectroscopy. 2020 , 1151, 122153	1
255	Physiological roles of transverse lipid asymmetry of animal membranes. 2020 , 1862, 183382	21
254	A comparative analysis of the essential oils from two species of garlic seedlings cultivated in China: chemical profile and anticoagulant potential. 2020 , 11, 6020-6027	2
253	The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats. 2020 , 193, 15-21	
252	Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics. 2020 , 21, 2595-2621	1
251	The humanized DRAGA mouse (HLA-A2. HLA-DR4. RAG1 KO. IL-2R g c KO. NOD) establishes inducible and transmissible models for influenza type A infections. 2020 , 16, 2222-2237	5

250	Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer. 2020 , 18, 1171-1182	2
249	Involvement of Kallikrein-Related Peptidases in Nervous System Disorders. 2020 , 14, 166	10
248	A droplet-based microfluidic viscometer for the measurement of blood coagulation. 2020 , 14, 014109	7
247	From surface to bulk modification: Plasma polymerization of amine-bearing coating by synergic strategy of biomolecule grafting and nitric oxide loading. 2020 , 5, 17-25	26
246	Self-assembling RATEA16 peptide nanofiber designed for rapid hemostasis. 2020 , 8, 1897-1905	12
245	Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles. 2020 , 20, 534-544	13
244	Etarrageenan-C-phycoerythrin based smart injectable hydrogels for accelerated wound recovery and real-time monitoring. 2020 , 109, 121-131	25
243	Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa. 2020 , 295, 517-528	6
242	Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. 2021 , 45, 100694	38
241	Microfluidic devices for studying coagulation biology. 2021 , 112, 1-7	4
240	A novel heptapeptide derived from <i>Crassostrea gigas</i> shows anticoagulant activity by targeting for thrombin active domain. 2021 , 334, 127507	6
239	The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. 2021 , 12, 496-511	13
238	Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. 2021 , 35, 195-203	16
237	Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes. 2021 , 253, 41-49	
236	Alcohol functionality in the fatty acid backbone of sphingomyelin guides the inhibition of blood coagulation.. 2021 , 11, 3390-3398	2
235	A novel anticoagulant peptide discovered from by combining bioinformatics with the enzymolysis strategy: inhibitory kinetics and mechanisms. 2021 , 12, 10136-10146	0
234	Engineered Sulfated Polysaccharides for Biomedical Applications. 2021 , 31, 2010732	9
233	Essential role of a carboxyl-terminal Helix motif in the secretion of coagulation factor XI. 2021 , 19, 920-930	2

232	Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor. 2021 , 137, 2981-2986	3
231	Investigation of structural, treatment and clinical characteristics of COVID-19 along with the challenges caused by its prevalence. 2021 ,	
230	Drupin, a thrombin-like protease prompts platelet activation and aggregation through protease-activated receptors. 2021 , 122, 870-881	
229	Fracture Mechanics of Human Blood Clots: Measurements of Toughness and Critical Length scales.	
228	Conformational Plasticity-Rigidity Axis of the Coagulation Factor VII Zymogen Elucidated by Atomistic Simulations of the N-Terminally Truncated Factor VIIa Protease Domain. 2021 , 11,	1
227	Proton Bridging in Catalysis by and Inhibition of Serine Proteases of the Blood Cascade System. 2021 , 11,	0
226	Global REACH 2018: Influence of excessive erythrocytosis on coagulation and fibrinolytic factors in Andean highlanders. 2021 , 106, 1335-1342	
225	Probing activation-driven changes in coagulation factor IX by mass spectrometry. 2021 , 19, 1447-1459	0
224	Role of Thrombin in Central Nervous System Injury and Disease. 2021 , 11,	10
223	Structure of human factor VIIa-soluble tissue factor with calcium, magnesium and rubidium. 2021 , 77, 809-819	2
222	When the Blood Hits Your Brain: The Neurotoxicity of Extravasated Blood. 2021 , 22,	6
221	Ontogeny of the digestive system and the profile of proteases in larvae of cachara (<i>Pseudoplatystoma reticulatum</i> Siluriformes: Pimelodidae) and its hybrid (<i>Pseudoplatystoma corruscans</i> [<i>Pseudoplatystoma reticulatum</i>]). 2021 , 99, 1135-1139	0
220	Protease Substrate-Independent Universal Assay for Monitoring Digestion of Native Unmodified Proteins. 2021 , 22,	2
219	Thrombin- and plasmin-like and platelet-aggregation-inducing activities of <i>Plumeria alba</i> L. latex: Action of cysteine protease. 2021 , 273, 114000	3
218	Structural basis of different surface-modified fullerene derivatives as novel thrombin inhibitors: insight into the inhibitory mechanism through molecular modelling studies. 2021 , 119,	
217	Cryo-EM structures of human coagulation factors V and Va. 2021 , 137, 3137-3144	5
216	Structural and Binding Effects of Chemical Modifications on Thrombin Binding Aptamer (TBA). 2021 , 26,	0
215	Characterization of AV422 from <i>Haemaphysalis flava</i> ticks in vitro. 2021 , 84, 809-823	0

214	The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations. 2021 , 9,	0
213	Prolonging coagulant activity of factor Xa under hemophilic conditions by site-specific N-glycosylation of the surface-exposed autolysis loop.	
212	Role of sequence and position of the cleavage sites in prothrombin activation. 2021 , 297, 100955	1
211	Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. 2021 ,	5
210	Molecular identification, characterization, and expression analysis of a serine protease inhibitor gene from cotton bollworm, <i>Helicoverpa armigera</i> (Lepidoptera: Noctuidae). 2021 , 81, 516-525	1
209	Fracture mechanics of blood clots: Measurements of toughness and critical length scales. 2021 , 48, 101444	5
208	Mechanisms of Thrombosis and Thrombolysis. 2022 , 11-23.e4	
207	Systematic studies on blood coagulation mechanisms of halloysite nanotubes-coated PET dressing as superior topical hemostatic agent. 2022 , 428, 132049	6
206	Hemostatic alteration in sickle cell disease: Pathophysiology of the hypercoagulable State. 2021 , 6, 1	
205	Thrombin.	1
204	The Role of Thrombin and Thrombin Receptors in the Brain. 2009 , 133-159	1
203	Serine Proteases. 2007 , 409-443	1
202	Interface Between Inflammation and Coagulation. 2001 , 402-422	3
201	Mechanisms for the anticoagulant effects of synthetic antithrombins. 1993 , 340, 213-26	1
200	Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins. 2009 , 539, 115-29	5
199	Fibrin in Nerve Tissue Engineering. 2021 , 1-43	1
198	Cytokines, coagulation and fibrinolysis. 1999 , 199-212	2
197	Oral Manifestations of Systemic Diseases and their Treatments. 2018 , 1-117	2

196	Hemostasis and Coagulation. 2001 , 161-176	3
195	Natural Anticoagulants and Their Pathways. 1999 , 447-476	1
194	Hemostasis in Xenotransplantation. 1997 , 126-139	1
193	Blood, Plasma Proteins, Coagulation, Fibrinolysis, and Thrombocyte Function. 1996 , 1651-1677	1
192	Blood clotting in invertebrates. 1996 , 15, 88-100	3
191	Calcium Binding Properties of Vitamin K-Dependent Clotting Factors. 1993 , 3-13	1
190	A Molecular Model of the Human Prothrombinase Complex. 2008 , 107-132	1
189	Bothrojaracin [A Potent Thrombin Inhibitor. 2010 , 179-199	1
188	Hematophagy and Inhibition of the Extrinsic and Intrinsic Tenase Complexes. 2010 , 219-237	1
187	Thrombin Inhibitors from Haematophagous Animals. 2010 , 239-254	1
186	Snake Venom Prothrombin Activators [The History. 2010 , 485-499	4
185	Tiny Ticks are Vast Sources of Antihemostatic Factors. 2010 , 113-130	1
184	Rational Approaches Towards Protease Inhibition: Predicting the Binding of Thrombin Inhibitors. 1994 , 137-149	4
183	Fibrinogen, Factor VII, and Plasminogen Activator Inhibitor-1. 1994 , 125-138	1
182	Proteases in Blood Clotting. 2004 , 457-463	4
181	CHARACTERISTICS OF SELECTED PROTEINS. 1993 , 167-191	1
180	THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-PROPERTY RELATIONSHIPS. 2003 , 405-416	3
179	Prosthetic Grafts. 2010 , 1335-1349	3

178	Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display.. 1994 , 269, 22129-22136	66
177	Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection.. 1994 , 269, 22137-22144	45
176	Key ligand interface residues in tissue factor contribute independently to factor VIIa binding.. 1994 , 269, 19399-19403	35
175	Glu192→Gln substitution in thrombin yields an enzyme that is effectively inhibited by bovine pancreatic trypsin inhibitor and tissue factor pathway inhibitor. 1994 , 269, 18395-18400	32
174	Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells.. 1994 , 269, 17329-17337	71
173	Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.. 1994 , 269, 15989-15992	19
172	Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.. 1994 , 269, 15898-15905	43
171	The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation.. 1994 , 269, 3682-3689	15
170	The role of thrombin's Tyr-Pro-Pro-Trp motif in the interaction with fibrinogen, thrombomodulin, protein C, antithrombin III, and the Kunitz inhibitors.. 1993 , 268, 19055-19061	56
169	The interaction of human factor VIIa with tissue factor.. 1992 , 267, 23696-23706	58
168	Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII.. 1992 , 267, 22206-22210	40
167	Liver-specific expression of the gene coding for human factor X, a blood coagulation factor.. 1992 , 267, 7395-7401	40
166	Calcium-dependent interaction between gamma-carboxyglutamic acid-containing and N-terminal epidermal growth factor-like modules in factor X. 1994 , 269, 26011-26016	17
165	PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.. 1993 , 268, 8458-8465	91
164	Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.. 1993 , 268, 8704-8710	38
163	Horseshoe crab coagulation factor B. A unique serine protease zymogen activated by cleavage of an Ile-Ile bond.. 1993 , 268, 21384-21388	50
162	Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue.. 1992 , 267, 17520-17525	95
161	The structure of a complex of bovine alpha-thrombin and recombinant hirudin at 2.8-Å resolution.. 1992 , 267, 17670-17678	44

160	Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains.. 1992 , 267, 14109-14117	167
159	Calcium affinity of the NH2-terminal epidermal growth factor-like module of factor X. Effect of the gamma-carboxyglutamic acid-containing module.. 1993 , 268, 26673-26678	36
158	Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A). 1994 , 269, 11374-11380	45
157	Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.. 1993 , 268, 24041-24046	12
156	Isolation and characterization of an intracellular serine proteinase inhibitor from a monkey kidney epithelial cell line.. 1993 , 268, 21560-21568	24
155	ISSUES IN THE ASSESSMENT OF PSA IMMUNOASSAYS. 1993 , 20, 607-619	32
154	CLINICAL AND LABORATORY EVALUATION OF THE HYPERCOAGULABLE STATES. 1995 , 16, 375-387	15
153	Macrocyclic inhibitors of serine proteases. 1997 , 41-76	8
152	Sodium-induced population shift drives activation of thrombin. 2020 , 10, 1086	5
151	Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex. 2020 , 295, 15198-15207	4
150	CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. 1997 , 29, 240-9	23
149	Hemostatic factors in tumor biology. 2000 , 22, 281-7	16
148	Thrombin-free polymerization leads to pure fibrin(ogen) materials with extended processing capacity.	3
147	Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance. 1995 , 227, 647-56	49
146	Bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells. 1999 , 67, 6130-8	39
145	Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. 1995 , 15, 1098-106	28
144	Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. 1996 , 94, 1705-12	18
143	Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta. 1997 , 81, 824-8	22

142	Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. 1994 , 94, 923-7	116
141	Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. 1997 , 99, 2446-51	92
140	Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. 1998 , 101, 993-1000	54
139	A Comparison of Murine and Human Factor XI. 1997 , 90, 1055-1064	1
138	Blood Coagulation in Hemophilia A and Hemophilia C. 1998 , 91, 4581-4592	3
137	Mechanism of Interfacial Exchange Phenomena for Proteins Adsorbed at Solid-Liquid Interfaces. 2003 ,	1
136	Protein Adsorption Kinetics. 2003 ,	1
135	Ixodes scapularis Tick Saliva Proteins Sequentially Secreted Every 24 h during Blood Feeding. 2016 , 10, e0004323	81
134	A Deep Insight into the Sialome of Rhodnius neglectus, a Vector of Chagas Disease. 2016 , 10, e0004581	15
133	An insight into the salivary gland and fat body transcriptome of Panstrongylus lignarius (Hemiptera: Heteroptera), the main vector of Chagas disease in Peru. 2018 , 12, e0006243	10
132	Isolation, cloning and structural characterisation of boophilin, a multifunctional Kunitz-type proteinase inhibitor from the cattle tick. 2008 , 3, e1624	83
131	Compounds from silicones alter enzyme activity in curing barnacle glue and model enzymes. 2011 , 6, e16487	30
130	Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance. 2012 , 7, e45111	8
129	Towards engineering hormone-binding globulins as drug delivery agents. 2014 , 9, e113402	11
128	Characterizing Protease Specificity: How Many Substrates Do We Need?. 2015 , 10, e0142658	19
127	A plasma proteolysis pathway comprising blood coagulation proteases. 2016 , 7, 40919-40938	15
126	[The hemostatic system and ischemic brain disease--general aspects]. 2002 , 59, 515-22	0
125	[Protein S and ischemic brain disease]. 2003 , 60, 93-6	0

124	Current trends in blood coagulation studies. 2020 , 19, 144-150	1
123	Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry. 2010 , 8 Suppl 3, s98-104	1
122	The optimal combined application technique of fibrin glue and bioabsorbable felt against alveolar air leakage. 2007 , 21, 762-769	6
121	Purification and Characterization of Serine Protease from Seeds of <i>Holarrhena antidysenterica</i> . 2008 , 7, 94-99	12
120	Diagnosis of Shoulder Arthroplasty Infection: New Tests on the Horizon. 2020 , 43, 76-82	1
119	Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia. 2020 , 15, 2217-2234	4
118	A novel anticoagulant protein from <i>Scapharca broughtonii</i> . 2002 , 35, 199-205	34
117	A novel anticoagulant protein with high affinity to blood coagulation factor Va from <i>Tegillarca granosa</i> . 2007 , 40, 832-8	24
116	Anticoagulant activities of curcumin and its derivative. 2012 , 45, 221-6	78
115	Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. 2012 , 45, 390-5	32
114	Antitcoagulant and antiplatelet activities of scolymoside. 2015 , 48, 577-82	34
113	Molecular drug targets and structure based drug design: A holistic approach. 2006 , 1, 314-20	37
112	Commentary on and reprint of Svensson PJ, Dahlback B, Resistance to activated protein C as a basis for venous thrombosis, in <i>New England Journal of medicine</i> (1994) 330:517B22. 2000 , 399-404	
111	Coagulation Theory, Principles and Concepts. 2000 , 493-520	
110	Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. 2000 , 96, 3459-3465	1
109	Transferring Groups by Displacement Reactions. 2001 , 589-675	
108	Coagulation Triggered by Erythrocyte Membrane and Its Possible Significance in Thrombus Formation. 2001 , 401-406	
107	GP IIb/IIIa?????. 2002 , 13, 151-157	

- 106 [Atherosclerosis of the aortic arch--a possible etiopathogenic factor in cerebral ischemic disease]. **2002**, 59, 169-76
- 105 [The hemostatic system and ischemic brain disease--specific aspects associated with cerebral circulation and clinical implications]. **2002**, 59, 523-9
- 104 ???A?????????2????????? (R2159C, R2209Q) ???VIII?????????????. **2002**, 13, 175-182
- 103 ?????????????????? ?X?????????2002, 13, 279-283 ○
- 102 Hemostasis and Coagulation. **2003**, 39-49
- 101 Object-Oriented Specification of Complex Bio-computing Processes: A Case Study of a Network of Proteolytic Enzymes. **2004**, 1-12 ○
- 100 Effect of FVIII on Clotting Time and Thrombin Potential in Tissue Factor-Activated Hemophilia A Plasma. **2005**, 156-161
- 99 Design and characterization of dipetacompinR10H, a dipetalogastin II-derived, classical competitive thrombin inhibitor. **2007**, 97, 139-145
- 98 Hemorrhagic diatheses. **2007**, 311-324
- 97 Clinical application of direct antithrombin inhibitors in acute coronary syndrome. **2007**, 93-107
- 96 Hemostasis and Coagulation. **2008**, 149-165
- 95 Current state of research on intrinsic pathway of blood coagulation ; Factor XII, factor XI and high-molecular-weight kininogen deficient mice. **2009**, 20, 323-328
- 94 Contact-Activation Pathways as Targets for New Anticoagulants. **2009**, 377-398
- 93 Faktor XI. **2010**, 191-202
- 92 Venous Pathology. **2010**, 163-176
- 91 Mechanisms of Thrombosis and Thrombolysis. **2011**, 29-43
- 90 Integration of Ligand-Based and Structure-Based Approaches for Virtual Screening of Factor Xa Inhibitors. **2012**, 141-154
- 89 Recent Insights into the Molecular and Cellular Contributions to Venous Thrombosis. **2012**, 71-102 ○

88 Protein Function | Proteases in Blood Clotting. **2013**, 52-57

87 Coagulation factor IX;its molecular structure and functional mechanism. **2013**, 24, 445-453

86 Clinical experience of intrapleural administration of fibrin glue for secondary pneumothorax with advanced lung cancer. **2014**, 28, 13-18

85 References. **1993**, 207-276

84 CHEMICAL AND POST-TRANSLATIONAL MODIFICATION OF PROTEINS. **1993**, 215-245

83 Mechanisms of Leukocyte-Mediated No-Reflow and Tissue Injury in the Microcirculation. **1994**, 331-351

82 Molecular Biology of Tf. **1995**, 235-247

81 Molekularbiologie des Protein-C- und Protein-S-Mangels. **1996**, 136-139

80 Structure-Based Design of Novel Heparin-Like Anticoagulants. **1998**, 163-173

79 Heparin-Binding Proteins - Pages 423-514. **1998**, 423-514

78 The Molecular Basis for Cross-Reacting Material Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII. **1998**, 91, 538-548 2

77 Activation of Clotting Factor XI Without Detectable Contact Activation in Experimental Human Endotoxemia. **1998**, 92, 3294-3301 2

76 Identification of Mutations and Polymorphisms in the Factor XI Genes of an African American Family by Dideoxyfingerprinting. **1998**, 92, 3309-3317

75 The Coagulation Pathway and Antithrombotic Strategies. **1999**, 1-39 4

74 Application of Immersed Boundary Method in Modelling of Thrombosis in the Blood Flow. **2015**, 108-116 0

73 Resorbable Polymeric Delivery Systems. 6973-6985

72 A Computational Model of the Biochemomechanics of an Evolving Occlusive Thrombus. **2018**, 125-144

71 Inhibition of Alpha Amylase and Alpha Glycosidase Enzymes by Various Earth Worm Extracts. **2018**, 11, 1261-1268

- 70 Transferrin plays a central role to maintain coagulation balance by interacting with clotting factors. 1
- 69 Comparative analysis of the influence of chlorine and fluorine anions on the fibrin polymerization. **2019**, 91, 27-37 1
- 68 Encyclopedia of Molecular Pharmacology. **2021**, 1-10
- 67 Effect of extracellular vesicles of follicular fluid on ovarian coagulation hemostasis. **2020**, 26, 18 1
- 66 Structure and Biological Function of Factor XI. **2008**, 68-79
- 65 Surgical Bleeding and Hemostasis. **2005**, 136-148
- 64 Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice. **2008**, 6, 306-14 19
- 63 Thrombin Generation in a Hemophilic Newborn. **2007**, 203-209
- 62 Thrombin Generation is Age-Dependent in Children as well as in Adults. **2007**, 235-239
- 61 Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis. **2021**, 32, 87-102 2
- 60 Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition. **2000**, 350 Pt 3, 701-7 1
- 59 Coagulation factor XI deficiency in Holstein cattle: expression and distribution of factor XI activity. **1994**, 58, 242-7 13
- 58 Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas. **1995**, 1, 153-60 7
- 57 Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. **2008**, 6 Suppl 2, s39-44 10
- 56 Cloning and comparison of factor X from rhesus monkey (*Macaca mulatta*). **2009**, 59, 476-81 1
- 55 Cloning of the full-length cDNA of porcine antithrombin III and comparison with its human homolog. **2009**, 59, 372-7 2
- 54 In Silico Design of Novel Anticoagulant Peptides targeting Blood Coagulation Factor VIIa. **2011**, 11, 83-94 1
- 53 Nonsense-mediated mRNA decay among coagulation factor genes. **2016**, 19, 344-9 1

52	Molecular genetic analysis of the F11 gene in 14 Turkish patients with factor XI deficiency: identification of novel and recurrent mutations and their inheritance within families. 2018 , 16, 105-113	2
51	An Ethanol-Free Autologous Thrombin System. 2018 , 50, 237-243	
50	Factor VII Gene Defects: Review of Functional Studies and Their Clinical Implications. 2019 , 23, 165-74	1
49	[Genetic diagnosis and bioinformatic analysis of a pedigree with inherited factor VII deficiency]. 2015 , 36, 163-5	
48	A critical review of surgical strategies to minimise venous stenosis in arteriovenous grafts. 2021 , 11297298211060944	
47	Chitin/corn stalk pith sponge stimulated hemostasis with erythrocyte absorption, platelet activation, and Ca-binding capabilities.. 2022 , 284, 118953	3
46	Anticoagulants. 2021 , 125-134	
45	The functional role of the autolysis loop in the regulation of Factor X upon hemostatic response.. 2021 ,	
44	Use of FLOSEAL \square as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.	0
43	The role of phosphatidylserine on the membrane in immunity and blood coagulation.. 2022 , 10, 4	2
42	Fluid-structure interaction analysis of eccentricity and leaflet rigidity on thrombosis biomarkers in bioprosthetic aortic valve replacements.	
41	Wounding response in Porifera (sponges) activates ancestral signaling cascades involved in animal healing, regeneration, and cancer.. 2022 , 12, 1307	1
40	A systematic approach for evaluating the role of surface-exposed loops in trypsin-like serine proteases applied to the 170 loop in coagulation factor VIIa.. 2022 , 12, 3747	1
39	Addressing Blood-Brain Barrier Impairment in Alzheimer's Disease.. 2022 , 10,	1
38	Measurement of prothrombin fragment 1+2 in cerebrospinal fluid to identify thrombin generation in inflammatory central nervous system diseases.. 2022 , 60, 103720	0
37	Retrospective examination of coagulation parameters in 33 patients with autoimmune coagulation factor deficiencies in Japan: A single-center analysis.. 2022 , 213, 154-162	1
36	G-Quadruplex-Functionalized Gold Nanoparticles for a Real-Time Biomolecule Sensor with On-Demand Tunable Properties.. 2022 ,	1
35	Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases.. 2022 , 10, 782608	1

34	Cryo-EM structure of the prothrombin-prothrombinase complex.. 2022,	1
33	Table_1.docx. 2018,	
32	Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X. 2022, 9,	
31	TREATMENT OF PATIENTS WITH BLEEDING DISORDERS. 1994, 38, 465-482	6
30	Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer. 2004, 2, 257-280	241
29	Fibrin in Nerve Tissue Engineering. 2022, 281-322	
28	Snake Venom Hydrogels as a Rapid Hemostatic Agent for Uncontrolled Bleeding. 2200574	1
27	Shining a light on thrombin activation. 2022, 139, 3451-3453	
26	Structural Insights into Blood Coagulation Factor VIII : Procoagulant Complexes, Membrane Binding, and Antibody Inhibition.	0
25	A comprehensive method to explore inhibitory kinetics and mechanisms of an anticoagulant peptide derived from <i>Crassostrea gigas</i> . 2022, 11, 1491-1499	
24	A hybrid fibronectin motif protein as an integrin targeting selective tumor vascular thrombogen. 2004, 3, 793-801	0
23	Molecular View into Preferential Binding of the Factor VII Gla Domain to Phosphatidic Acid. 2022, 61, 1694-1703	
22	Fibrinogen, Fibrin, and Fibrin Degradation Products in COVID-19. 2022, 23,	1
21	Highly Sensitive Electrochemical Immunoassay Using Signal Amplification of the Coagulation Cascade.	0
20	Warfarin-induced Skin Necrosis and Venous Limb Gangrene: Lesson from a Case Induced the Serious Complications by the Anticoagulants During the Treatment of Acute Artery Occlusion. 2007, 18, 13-19	0
19	Binding modes of prothrombin cleavage site sequences to the factor Xa catalytic triad: Insights from atomistic simulations. 2022, 20, 5401-5408	0
18	Phosphatidylserine Regulation of Coagulation Proteins Factor IXa and Factor VIIIa.	0
17	Fluid-structure interaction analysis of eccentricity and leaflet rigidity on thrombosis biomarkers in bioprosthetic aortic valve replacements.	0

16	Modern Aspects of Anticoagulation System Disorders Diagnosis in Children with Different Polymorphisms in Coagulation Genes. Initial Results. 2022 , 19, 326-335	1
15	Cryo-EM structures of coagulation factors. 2022 , 6,	0
14	Systems Biology Approach for Personalized Hemostasis Correction. 2022 , 12, 1903	0
13	Identification of non-neutralizing anti-factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency.	0
12	Activity Sensing of Coagulation and Fibrinolytic Proteases.	0
11	Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. 2022 , 9, 437	0
10	Factor Xa Induces Cytokine Production and Expression of Adhesion Molecules by Human Umbilical Vein Endothelial Cells. 1998 , 161, 4318-4324	20
9	Isolation and determination of biochemical nature of water soluble anticoagulant from earthworm. 2011 , 12, 75-77	0
8	Oxazolidinones as Versatile Scaffolds in Medicinal Chemistry.	1
7	Hemostasis during cardiopulmonary bypass. 2023 , 295-309	0
6	Plasma proteomic signature of fatty liver disease: the Rotterdam Study. Publish Ahead of Print,	0
5	Development and applications of mRNA treatment based on lipid nanoparticles. 2023 , 65, 108130	0
4	A molecular dynamics simulation study to understand the effect of cholesterol and tissue factor palmitoylation on tissue factor-factor VIIa-factor Xa ternary complex in different lipid environments. 2023 , 21, 917-932	0
3	Pathophysiologie der Haut bei thermischen Läsionen. 2022 , 31-49	0
2	Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway. Volume 16, 1027-1042	0
1	Monitoring prothrombin activation in plasma through loss of Förster resonance energy transfer. 2023 ,	0